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 1
1 Introduction  
 
Speciation of arsenic species in biological and environmental samples is important 
because bioavailability and toxicity of arsenic species strongly dependent on their chemical 
form (Gong et al., 2002 and Sakai et al., 2001). Thus, studies in the chemical forms of arsenic, 
their transformation, persistence and bioavailability are important in the understanding of 
levels of human exposure to arsenic. Arsenic is a human carcinogen that categorized first in a 
list of hazardous substances by the Agency for Toxic Substances and Disease Registry and the 
United States Environmental Protection Agency (ATSDR 2005). Chronic ingestion of high 
levels of arsenic in drinking water has been correlated with skin, bladder, and lung cancer, as 
well as hypertension and cardiovascular effects. However, mechanisms responsible for arsenic 
toxicity, metabolism and carcinogenic effects are not well understood. Speciation studies of 
arsenic in human urine have shown that dimethylarsinic acid (DMAs(V)) and 
monomethylarsonic acid (MMAs(V)) are the major human metabolites of inorganic arsenic 
species. These methylated arsenic species are a result of biomethylation, which is the major 
process of human arsenic metabolism in liver. Biomethylation of arsenic involves a stepwise 
reduction of pentavalent arsenic to trivalent arsenic followed by oxidative addition of a methyl 
group to the trivalent arsenic. In humans (Cullen and Reimer 1989) the process stops with the 
formation of DMAs(V) and probably dimethylarsinous acid (DMAs(III)). In microorganisms, 
the final product is mainly trimethylarsine oxide (TMAsO) with some trimethylarsine 
(TMAs(III)). Recently intermediates of monomethylarsonous acid (MMAs(III)) and 
DMAs(III), have been discovered in human urine that is direct evidence for biomethylation 
pathway (Aposhian et al., 2000a & 2000b; Sampayo-Reyes et al., 2000; Le et al., 2000a & 
2000b; Del Razo et al., 2001; Mandal et al., 1997). Recent studies have also showed that the 
methylated trivalent arsenic species are as toxic as or even more toxic than the inorganic 
arsenic species (Styblo et al., 1997; Lin et al., 1999 & 2001; Thomas et al., 2001; Petrick et 
al., 2000 & 2001; Mass et al., 2001; Vega et al., 2001; Chen et al., 2003; Andrewes et al., 
2003). Previously, the methylation of arsenic has been considered as a detoxification process 
because MMAs(V) (LD50 800–1600 mg kg-1) and DMAs(V) (LD50 800–2600 mg kg-1) are 
less toxic than the inorganic arsenic species (LD50 10–20 mg kg-1). However, there is a doubt 
whether arsenic biomethylation is strictly a detoxification process, since toxicity of 
intermediary arsenic metabolites (MMAs(III) and DMAs(III)) was found more in humans. 
There is much interest in the determination of MMAs(III) and DMAs(III) in studies of arsenic  
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metabolism and health effects. Thus an increasing demands for analytical techniques 
that are capable of speciation the arsenic metabolites in human and animal samples. 
          In has been considered that determination of total arsenic concentration is insufficient 
for clinical and environmental considerations. Therefore, for evaluation of the toxic potential 
to humans and the environment, it is necessary to investigate not only the total arsenic 
concentrations but also to differentiate each arsenic species.  
 
1.1 Inductively Coupled Plasma Mass Spectrometry in Environmental Analysis 
          In recent years, most environmental scientists were interested in trace analysis of 
environmental samples. Currently, various elements, which were not used in past, are 
consumed in modern industries for production of new materials. New types of environmental 
pollution must be resulted due to disposal of industrial products. Therefore it requires 
analytical techniques that are able to rapid measuring of multielement simultaneously such as 
ICP-MS (Meyers 2000). 
          ICP-MS is combination of two analytical tools (inductively coupled plasma (ICP) and 
mass spectrometry (MS). This combination makes an instrument with powerful potential for 
multielement trace analysis. The main advantages of ICP-MS compared to other analytical 
methods are increased sensitivity, wide dynamic range, high selectivity, rapid multielement 
analysis, low background, and the ability to measure specific isotopes. In spite of mentioned 
advantages, it should be noted that ICP-MS has lower precision compared with inductively 
coupled plasma-atomic emission spectrometry (ICP-AES) and atomic absorption 
spectrometry (AAS). Also in ICP-MS, the total dissolved salts should be less than 1000 ppm. 
Other disadvantages of ICP-MS were included in matrix effects and instrument’s cost.  
 
1.1.1 Instrumentation 
          A schematic of the main components of a typical ICP-MS instrument is shown in 
Figure 1.1. The sample introduction into ICP was done using a nebulizer combined to a spray 
chamber. The sample was ionized in ICP and then charged ions were transferred to interface 
between plasma and mass analyser that consists of two cones named the sampling cone and 
the skimmer cone. Electrostatic lenses extract the positively charged ions from skimmer cone 
and focus the ion beam in a suitable form for transmission through a mass filter. The 
quadrupole mass filter transmits the ions of a particular mass to charge ratio (m/z) to an ion 
detector. 
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Figure 1.1 Schematic of a typical ICP-MS instrument (modified from the original drawing 
provided by Agilent Technologies). 
 
 
The ICP torch (Figure 1.2) is consisting of three concentric tubes and located inside a 
copper coil that is connected to a radiofrequency (RF) generator. The plasma is generated at 
the end of the quartz torch via a tesla spark and maintained by using high frequency 
electromagnetic field. The RF flows in the copper coil and induces oscillating magnetic fields. 
Electrons and ions flow at rapid acceleration rates while pass through the oscillating 
electromagnetic field. Then accelerated electrons and ions ionized further due to collision with 
unionized argon gas (Meyers 2000).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic diagram of an ICP system. 
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1.2 Liquid Chromatography 
          The basis of liquid chromatography (LC) is a liquid mobile phase. Separation in liquid 
chromatography are carried out by introducing sample onto a column filled with a solid 
stationary phase while a liquid mobile phase is pumped through the column continuously. In 
classic liquid chromatography, introduced by Tswett in 1906, were applied glass columns 
with inner diameter of 1 to 5 cm and a length of 50 to 500 cm. However the separations were 
long and attempts by using a vacuums or pumps had not any improvement. Later it was 
recognized that a higher performance could only be achieved by reduction of the particle size 
of stationary phase. The practical improvement resulted at the end of the 1960s by introducing 
particles with diameters of up to 3 or 10 µm (Kellner et al., 1998). 
        In early LC stationary phases a liquid stationary phase coated onto a solid support, but 
modern LC stationary phases are usually comprised of chemically modified silica or 
polymers. The analytes during passing through the column interact with both the stationary 
and the mobile phases. The time that each analyte resides in the column depends on 
interaction of the analyte with both phases. Thus, separation is based on different between 
residual times of analyts in column (Cornelis et al., 2003). LC is applied for separation non-
volatile compounds as well as the compounds that decompose at high temperatures. There is a 
variety of stationary phases are commercially available. Furthermore, separations can be 
further enhanced by the addition of additives to the mobile phase. Usually, minimum sample 
preparation is required and LC can readily interface to ICP-MS.  
 
1.2.1 Effecting Variables in Liquid Chromatography Separation 
          For optimization of LC separation should be considered a variety of variables. The 
interaction analyte with both stationary and mobile phases are based on dipole forces, 
electrostatic attractions and hydrophobic interactions. Thus, knowledge of structure of analyte 
is useful in prediction of its behaviour during the separation. Generally, compounds that have 
different polarity or chemical structure separate easier. The selection of the stationary phase is 
usually based on the nature of the analytes for example; anionic species would be separated 
using an anion exchange column. The analytes may derivative before the separation to make 
easy separation or detection (Toyo’oka 1999; Liu and Lee 1999). The composition of mobile 
phase is an important variable in separation. The mobile phase may consist of one component 
such as methanol, or a mixture of solvents and/or aqueous solutions such as buffers. The 
sample must be soluble in the mobile phase to prevent the precipitation of sample within the 
Introduction 
 
 
 5
column. For better separation chiral additives, ion pair reagents, and surfactants may be added 
to get a better separation. The composition of the mobile phase alters during the separation in 
gradient separations but in isocratic separations the mobile phase composition is held constant 
throughout the separation. Gradient separations are often utilized to decrease the time of 
separation or better resolution. The flow rate of the mobile phase is also a significant variable 
because of its effects on the time of separation. Increasing the flow rate will decrease the 
separation time.  It should also be considered the method of detection while optimization of 
the flow rate. Fluctuations in temperature may change retention time of analyte. Thus HPLC 
columns are frequently housed in water jackets or ovens to control the column temperature. 
Generally, increases in temperature cause a decrease in analyte retention time due to reduction 
of mobile phase viscosity and increase the rates of diffusion. 
1.2.2 Characteristic Parameters of a Chromatogram 
  The term retention time (tr) is defined as the time that analyte take to pass through the 
column and reach the detector. Separation is based on difference between retention time of 
sample and standard. The capacity factor, k´, represents the normalized retention time for an 
analyte and is calculated using equation (1.1) 
( )
0
0'
t
ttk r−=                            (1.1) 
Where tr is retention time of analyte and to is retention time of a analyte that is not retained by 
the stationary phase. 
The selectivity factor shows ability of system in separation of two analytes and is indicated by 
α in chromatography. The selectivity is the ratio of capacity factor of two analytes. 
 '
2
'
1
k
k=α                                   (1.2) 
The resolution, Rs, shows the efficiency of a separation. The resolution is calculated by 
dividing the distance between two chromatographic peaks by the average of their widths at the 
base. 
( )212
1
tt
r
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tR
+
∆=                  (1.3) 
Analyte peaks in LC separations are Gaussian shape and a mathematical expression for the 
symmetry of a chromatographic peak is the peak asymmetry factor, As. The ideal peak in LC 
should be narrow and have a peak asymmetry factor of 1. 
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 Two terms that are frequently used in LC are plate height (H) and plate count (N). These 
terms relate to a column’s chromatographic efficiency. 
The plate height is determined by dividing the length of the stationary phase, L, by the plate 
count. 
N
LH =               (1.4) 
One method for calculation of N is to determine the width peak at half of maximum height, 
W1/2, and replace in this equation (1.5). 
                                                2
21
254.5
W
tN r=                            (1.5) 
 
1.2.3 Liquid Chromatographic Stationary Phases 
1.2.3.1 Normal Phase Chromatography (NPC) 
          Normal phase chromatographic systems are involving a polar stationary phase and a 
nonpolar mobile phase such as hexane. In earlier NPC was frequently used unmodified silica 
or alumina but the obtained peak shapes were often broad and irreproducible retention times. 
The problems were improved with modified stationary phases that have a polar functional 
group such as cyano that is chemically bonded to the silica. In spite of NPC allows analytes 
that are insoluble in polar solvents to be separated but it has limited application in the area of 
elemental speciation. The major limitation of this technique is the nonpolar mobile phase, 
which is incompatible with most elemental detectors used in speciation analysis and also the 
nature of the nonpolar mobile phase, in which many of real samples are not soluble. 
 
1.2.3.2 Reversed Phase Chromatography (RPC) 
          RPC is one of LC techniques that widely was used in elemental speciation. It is used to 
separate nonpolar and/or slightly polar species. The polar mobile phases used are typically 
aqueous or a mixture of water and an organic modifier such as methanol or acetonitrile. The 
stationary phase is silica with silanol-OH group replaced by alkyl chains. Separation is based 
on the hydrophobicities of the species. Separations may be influenced by changing variables 
such as functional group of stationary phase, pH, ionic strength, organic modifiers, and the 
gradient program. The pH of the mobile phase is an important parameter in RPC which affects 
the charge of the analyte and its retention on the column. Traditional silica stationary phases 
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cannot tolerate pHs below 2 or above 7 due to hydrolysis of the stationary phase. Recently, 
manufacturers have produced silica-based reversed phase stationary phases that can tolerate 
pHs of 2 to 10. Reversed phase stationary phases may also be made of polymeric materials, 
but silica-based columns are still the most commonly used.  
 
1.2.3.3 Reversed Phase Ion Pair Chromatography (IPC) 
          Reversed phase ion pair chromatography has similar stationary phases to RPC but an 
ion pair reagent is added to the mobile phase. An ion pair reagent is a salt including a cationic 
or anionic polar head group and a nonpolar tail such as sodium alkyl sulfonate and tetraalkyl 
ammonium salts. IPC can simultaneously separate anions, cations, and noncharged species. 
The separation mechanism in IPC has not completely understood. One theory states that an 
ionic analyte is electrostatically attracted to the charged portion of the ion pair reagent. Then 
charge neutralization causes the charged analyte to be retained by the nonpolar stationary 
phase. Another theory is that the hydrophobic portion of the ion pair reagent adsorbs to the 
stationary phase and a pseudo ion exchange stationary phase is formed. Thus, charged species 
interact with the pseudo ion exchange stationary phase (Skoog  and Leary , 1992). 
 
1.2.3.4 Ion Exchange Chromatography (IEC) 
          IEC is used to separate free ions and ionisable species. The stationary phase consists of 
a substrate such as a polystyrene-divinylbenzene polymer or silica which has an ionic 
functional group such as quaternary ammonium or sulfonate. IEC is commonly divided to 
cation exchange chromatography and anion exchange chromatography depending on the 
functional group of stationary phase. Analytes will interact with the stationary phase 
electrostatically if they have opposite charge to charge of functional group of stationary phase. 
The retention time of an analyte depends on electrostatic force. Mobile phases used in IEC 
separations are typically aqueous solutions of inorganic salts. IEC is compatible with element 
selective detectors such as an ICP-MS. Also IEC can be utilized for the purpose of sample 
cleanup prior to analysis and sample preconcentration. 
 
 
 
 
Introduction 
 
 
 8
1.3 High Performance Liquid Chromatography (HPLC) 
          HPLC is a widely separation method in analytical chemistry and speciation analysis. 
Many different HPLC stationary phases are commercially available. In fact HPLC is a subset 
of liquid chromatography. In HPLC the stationary phase particles have small diameters with 
order of 3-5 µm. The mobile phase is pumped at high pressure through the stationary phase. 
Pumping a viscous liquid through the column packed with small very particle produce high 
pressure. Therefore, HPLC is also called “high pressure liquid chromatography”.    
          Both the mobile and the stationary phases may be modified in order to achieve the 
desired separation. The most common mobile phases are buffer solutions which mixed with 
organic solvents like methanol or acetonitrile. The solutions have always to be degassed 
before experiment to avoid formation of air bubbles in the system. All mentioned variables 
that are effective in LC separation (pH, temperature, concentration of the mobile phase 
constituents, and flow rate) must be considered for optimization of HPLC system.  HPLC can 
be easily interfaced with element-specific detectors such as ICP-MS, ICP-AES and FAAS 
since the sample introduction flow rate of such detectors comparable to those employed for 
the elution (0.5 – 2.0 mL.min-1).  
 
1.3.1 Instrumentation 
          The components of a HPLC unit are included a reservoir containing mobile phase, a 
pump to pressurize the liquid mobile phase, an injector for injection of a small volume of the 
sample under high pressure, a separation column containing stationary phase, a detector to 
detect components that leave the column, and finally recorder for gathering the detector 
signal. Structure of a HPLC unit is simply shown in Figure 1.3. 
 
 
 
 
 
 
 
 
Figure 1.3 Structure of a HPLC unit. 
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1.4 Hyphenated (Coupling) Techniques 
          Hyphenated techniques play an important role in online chromatographic separation or 
enrichment of elements prior to detection. Hyphenated techniques are favourably applied for 
the determination of elemental species at trace levels. Coupling separations as online 
compared with offline techniques showed much better repeatability of analytical results, 
minimized contamination, and they can be run automatically (Heumann 2002). The 
hyphenated systems that are frequently applied for elemental speciation are coupling of HPLC 
or GC with an atomic spectrometric method as well as capillary electrophoresis (CE). 
Inductively coupled plasma atomic emission spectrometry (ICP-AES) and ICP-MS have 
much attention due to their capability in multi elemental analysis. The coupling of HPLC with 
ICP-MS offers some advantages such as high sensitivity; capability of multi-element analysis, 
wide dynamic range, and isotope ratio measurement capability (Gong et al., 2002). A wide 
range of applications of HPLC-ICP-MS for arsenic speciation has been reported (Mandal et 
al., 2001; Le et al., 1998; Nakazato et al., 2000; Mattusch and Wennrich 1998; Guerin et al., 
2000; Saverwyns et al., 1997; Moldovan et al., 1998; Woller et al., 1998; Saeki et al., 2000). 
ICP-AES usually allows element detection in range of ng mL–1 but ICP-MS is able to detect 
many elements in range of pg mL–1. The interfacing of HPLC or GC with ICP-AES and ICP-
MS detection are relatively simple (e.g. in Rottmann and Heumann 1994; Gallus and 
Heumann 1996). The most frequent application of hyphenated techniques in elemental 
analysis is speciation, which is important in environmental sciences, clinical chemistry, 
toxicology, and nutrition. Figure 1.4 shows the hyphenated techniques using ICP-MS as 
detection (Szpunar 2005) 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Hyphenated systems using ICP-MS detection (modified from the original 
schematic provided by Szpunar 2005) 
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1.5 Definition of Metal Speciation 
          Metal speciation is the different chemical and physical form of metals in the 
environment. It includes all form of metals such as dissolved metal ions, complexes, colloids, 
metal into or adsorbed on particle or metal solids which present in the sediment. The 
environmental chemistry of arsenic is complex because arsenic has different chemical forms 
in environmental samples and different toxicological effects on the environment (Reeve 
1994). 
 
1.5.1 Sources of Arsenic in the Environment 
          Elemental arsenic (As) has an atomic number of 33 and an atomic mass of 74.91. 
Arsenic is a metalloid widely distributed in the earth’s crust. It can exist in four valency 
states; –3, 0, +3, and +5. Elemental arsenic and arsine (–3) can exist in strongly reducing 
environments only. Arsenite (+3) may be the main form under moderately reducing 
conditions but arsenate (+5) is generally the stable in oxygenated environments. Arsenic and 
its compounds usually occur in trace quantities in all rocks, soil, water and air. Soils may 
contain arsenic levels between 0.1 and 40 ppm (Yan-Chu 1994; WHO 1981). Arsenical salts 
have different aqueous solubility depending on the pH and the ionic environment (Gomez-
Caminero et al., 2001).  
          Arsenic is present in more than 200 mineral species, the most common is arsenopyrite. 
It has been estimated that about one-third of the atmospheric arsenic has natural origin. 
Volcanic action is the most important natural source of arsenic. Inorganic arsenic of 
geological origin contained in drinking-water in several parts of the world, for example 
Bangladesh. Organic arsenic compounds such as arsenobetaine, arsenocholine, 
tetramethylarsonium salts, arsenosugars and arsenic-containing lipids are mainly found in 
marine organisms. Some arsenic species present in biological samples are listed in Table 1.1.  
          Numerous man-made arsenic compounds as used in agriculture gradually accumulated 
in the soil (Azcue and Nriagu 1994).  The use of pesticides containing arsenic and arsenic in 
the preservation of timber has also led to contamination of the environment. It has been 
estimated that 70% of the world arsenic production is used in timber treatment as copper 
chrome arsenate (CCA), 22% in agricultural chemicals, and the rest in glass, pharmaceuticals 
and non-ferrous alloys. Different sources of human exposure to arsenic and resulted toxicity is 
shown in Figure 1.5.  
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Arsenic is detected at a significant concentration [> 1 mg As per litre (1ppm as As)] in several 
human foods such as fish, shellfish, mushrooms, and algae (Byrne et al., 1995; Cullen and 
Reimer, 1989; Edmonds and Francesconi, 1993; Francesconi and Edmonds, 1997; Lai et al., 
1997; Shibata and Morita, 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 List of some arsenic species present in biological samples 
Name Abbreviation  Chemical formula 
Arsenite, Arsenous acid As(III) As(OH)3 
Arsenate, Arsenic acid As(V) AsO(OH)3 
Monomethylarsonic acid MMAs(V) CH3AsO(OH)2 
Monomethylarsonous acid MMAs(III) CH3As(OH)2 
Dimethylarsinic acid DMAs(V) (CH3)2AsO(OH) 
Dimethylarsinous acid DMAs(III) (CH3)2AsOH 
Trimethylarsine oxide TMAsO (CH3)3AsO 
Trimethylarsine TMAs(III) (CH3)3As 
Arsenobetaine AsB (CH3)3As+CH2COO- 
Arsenochline AsC (CH3)3As+CH2CH2OH 
Tetramethylarsonium ion Me4As+ (CH3)4As+ 
Dimethylarsinoyl ethanol DMAsE (CH3)2AsOCH2CH2OH 
Arsenosugars X, XI, XII, XIII, XIV, XV see structure below 
 R X Y 
X (CH3)2As(O)- -OH -OH 
XI (CH3)2As(O)- -OH -OPO3HCH2CH(OH)CH2OH 
XII (CH3)2As(O)- -OH -SO3H 
XIII (CH3)2As(O)- -OH -OSO3H 
XIV (CH3)2As(O)- -NH2 -SO3H 
XV (CH3)2As+- -OH -OSO3H 
O O CH2 CH2CH YCH2
R
OH OH 
X 
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Figure 1.5 Sources of human exposure to arsenic and resulted toxicity (modified from Roy 
and Saha 2002) 
 
1.5.2 Biomethylation of Arsenic 
          The term biomethylation describes the formation of both volatile and nonvolatile 
methylated compounds of metals (Bentley and Chasteen 2002). The major volatile arsenic 
compounds formed by biomethylation have the structure (CH3)nAsH3-n; for n =1, 2, and 3, the 
products are mono-, di-, and trimethylarsine, respectively. The major nonvolatile arsenic 
compounds are methylarsonate and dimethylarsinate. Biomethylation of arsenic happens not 
only in microorganisms but also in algae, plants, animals, and humans. 
          Biomethylation of arsenic is the major metabolic pathway for the metabolism of 
inorganic arsenic humans and other mammals (Lu et al., 2003). The full pathway as seen for 
many fungi involves the reduction of a pentavalent arsenic species to a trivalent arsenic 
species followed by the addition of a methyl group to the trivalent arsenic (Challenger 1945; 
Cullen et al., 1984 & 1989). Specifically, as shown in Figure 1.6, first inorganic arsenate 
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As(V) is reduced to arsenite As(III) and then As(III) is oxidatively methylated to 
monomethylarsonic acid (MMAs(V)). MMAs(V) is then reduced to monomethylarsonous 
acid (MMAs(III)) and further methylated to dimethylarsinic acid (DMAs(V)). Similarly, 
further steps produce dimethylarsinous acid (DMAs(III)) and trimethylarsine oxide (TMAsO), 
which can be reduced to trimethylarsine (TMAs(III)).  
                      
Figure 1.6 Pathway of arsenic methylation, showing alternate steps of two-electron reduction 
(2e-) and oxidative addition of a methyl group (CH3+). 
 
          In past has been considered that the metabolic pathway did not usually continue beyond 
than the dimethylarsenic species in humans and most animals (Cullen and Reimer 1989). Thus 
biomethylation of arsenic has previously been considered a detoxification process. However, 
this suggestion was changed with finding trivalent methylation metabolites, MMAs(III) and 
DMAs(III) in human urine (Aposhian et al., 2000a & 2000b; Sampayo-Reyes et al., 2000; Le 
et al., 2000a & 2000b; Del Razo et al., 2001; Mandal et al., 1997). The numerous studies 
showed these metabolites have higher toxicity than the inorganic arsenic species (Styblo et al., 
1997; Lin et al., 1999 & 2001; Thomas et al., 2001; Petrick et al., 2000 & 2001; Mass et al., 
2001; Vega et al., 2001; Chen et al., 2003; Andrewes et al., 2003). It is now believed that the 
methylation of inorganic arsenic may not be a detoxification mechanism and could be an 
activation process (Kitchin 2001; Hughes 2002; Styblo 2002). As a consequence, much 
attention has been paid to studies of the toxic effects of these metabolites.  
Recently it has been suggested that arsenic-glutathione (As-GSH) complexes are 
directly involved in the methylation of inorganic arsenic metabolites (Hayakawa et al., 2005). 
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Therefore, a new metabolic pathway has been presented (Figure 1.7), in which trivalent 
metabolites are converted to the less toxic pentavalent species. This new pathway is in 
agreement with the concept that oxidation of arsenic is detoxification. In brief, in the new 
pathway, both arsenic triglutathione (ATG) and monomethylarsonic diglutathione (MADG) 
are substrates for human arsenic methyltransferase Cyt19. Arsenite is metabolized and 
converted to DMAs(V) by Cyt19 via formation of As-GSH complexes. 
 
 
 
Figure 1.7 A new metabolic pathway of inorganic arsenic via arsenic–GSH complexes 
(presented by Hayakawa et al., 2005) 
 
1.5.3 Cytotoxicity and Toxicity 
          The toxicity of arsenic is dependent on its chemical species. Recently has shown that 
trivalent methylated arsenicals are potent cytotoxins in cultured primary rat hepatocytes. In 
these cells, both methylarsine oxide (MeAs(III)O) and dimethylarsinous iodide (Me2As(III)I) 
were significantly more cytotoxic than are arsenite, arsenate, methylarsonic acid and 
dimethylarsinic acid (Styblo et al., 1999b, 2000). Similarly (Table 1.2), in primary human 
hepatocytes and in cell lines that are derived from tissues (skin, lung, and urinary bladder), 
both methylarsine oxide and dimethylarsinous iodide are potentially cytotoxic (Styblo et al., 
1999b, 2000). 
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Table 1.2 Cytotoxicity in rat and human cells of arsenicals containing trivalent arsenica 
 
  
Estimated LD50 (µM) 
 
Cell type 
 
NaAs(III)O2
 
MeAs(III)O 
 
( Me2As(III))-GS 
Primary rat hepatocytes ~ 10 2.8 14.5 
Primary human hepatocytes > 20 5.5 > 20 
Human epidermal keratinocytes > 20 2.6 8.5 
Human bronchial  epithelial 
cells 
 
3.2 
 
2.7 
 
6.8 
Urotsa cells 17.8 0.8 14.2 
 
a Estimated LD50 (concentration of an arsenical that results in 50% decrease in cell viability) 
as determined by formazan dehydrogenase (MTT) assay after a 24-h exposure to these 
arsenicals. Estimates based on cell survival assays in which triplicate or quadruplicate assays 
of cell viability were performed for each concentration of arsenical tested. The Urotsa cell line 
is derived from SV40-transformed human bladder epithelial cells. All data are taken from 
Styblo et al. (2000). 
 
          In a human liver cell line (Chang cells), MMAs(III) showed more potent cytotoxin than 
arsenite, arsenate, methylarsonic acid, or dimethylarsinic acid (Petrick et al., 2000). In an in 
vitro assay contains rat liver cytosol showed that both MMAs(III) and DMAs(III) were 
associated with specific cytosolic proteins. While, pentavalent methylated arsenicals 
((MMAS(V) and DMAs(V)) were not bound to specific cytosolic proteins (Styblo and 
Thomas, 1997a). It suggests that generated MMAs(III) and DMAs(III) during the arsenic 
metabolism in the cell interact with cytosolic proteins and may produce toxic effects.  
          Modes of cell death have been examined in mouse macrophages exposed to arsenate, 
arsenite, methylarsonic acid, dimethylarsinic acid, or trimethylarsine oxide ((CH3)3AsO) 
(Sakurai et al., 1998). Both arsenate and arsenite were relatively potent cytotoxins with 50% 
inhibitor concentrations (LD50) of 500 and 5 µM, respectively). In contrast, the methylated 
arsenicals were much less potent cytotoxins (LD50 ≥ 5 mM for all species). In a human 
promyelocytic leukemia cell line (HL-60 cells), exposure to 1-5 mM dimethylarsinic acid 
induced apoptotic but exposure to up to 50 mM methylarsonic acid has not any effect (Ochi et 
al., 1996). Apoptosis was also induced in this cell line by arsenate (0.1 mM) and by arsenite 
(0.02 and 0.05 mM). In comparison, As2O3 induces differentiation and apoptotic death in 
various leukemic cell lines (Zhu et al., 1999) and is now used therapeutically in acute 
promyelocytic leukaemia (APL). It is possible that either methylarsonous acid or 
dimethylarsinous acid could be more efficacious in the treatment of APL and their effects on 
the viability, proliferation and differentiation of leukemic cells are now under investigation. 
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Aposhian and coworkers (Petrick et al., 2001) have compared the acute toxicity of sodium 
arsenite and methylarsonous acid in hamsters. The estimated LD50 for arsenite was 112 µmol 
per kg; for methylarsonous acid 29.3 µmol per kg. This report that methylated arsenicals 
containing As(III) are more toxic than arsenite in animal. 
 
1.5.4 Methylated Metabolites of Arsenic 
          As mentioned before, it is believed that the methylation of arsenic in human may be a 
toxification pathway because finding trivalent methylation metabolites in human urine that 
have more toxicity than inorganic arsenicals. Thus current interest has been centred on studies 
of the toxic effects of the trivalent methylated species of arsenic MMAs(III), DMAs(III). 
TMAs(III) may be formed by reductive processes from pentavalent arsenicals, exist in higher 
concentrations in rat tissues than in human tissues. 
 
1.5.4.1 MMAs(III) 
          Recently, MMAs(III) has been found in urine of humans exposed to arsenic without 
(Aposhian et al., 2000a) and with concomitant treatment with chelators (Aposhian et al., 
2000b). MMAs(III) is an excellent choice as arsenic carcinogenesis because humans excrete 
much more MMAs than other species. It could be the reason that humans are unusually 
sensitive to arsenic-induced carcinogenesis. Some of the biological activities MMAs(III) are 
inhibition of GSH reductase (Styblo et al., 1997), thioredoxin reductase (Lin et al.,1999) cell 
toxicity (Petrick et al., 2000), and genotoxicity (Mass et al., 2001). This certainly is an 
impressive list of biological activities for a methylated arsenic metabolite that formerly 
thought to be a “detoxified” form of arsenic. 
 
1.5.4.2 DMAs(III) 
         The presence of  DMAs(III) and MMAs(III) has been demonstrated in human urine of 
arsenic-exposed humans administered 2,3- dimercapto-1-propane sulfonate (a chelator) (Le et 
al., 2000). In a study of hamsters given arsenate (Sampayo-Reyes et al., 2000), substantial 
hepatic concentrations of trivalent MMAs and DMAs were found in addition to the expected 
pentavalent MMAs and DMAs. The capacity to separate the trivalent forms of the methylated 
arsenic species from the pentavalent forms has recently been developed (Del Razo et al., 
2000; Sampayo-Reyes et al., 2000; Le et al., 2000). Some of the biological activities that 
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DMAs(III) is known to possess in various experimental systems are similar to MMAs(III). At 
physiological pH, DNA is negatively charged and many arsenic chemical forms have also 
negative charge. The negatively charged arsenic forms would not be expected to easily 
interact with DNA because of electrostatic repulsion. When arsenic is successively 
methylated, the ionisable hydroxy group are replaced by uncharged methyl group. Thus, a 
molecule of DMAs(III) may be able to directly interact with DNA more easily than trivalent 
arsenite. 
 
1.5.4.3 TMAs(III) 
          TMAs(III) may be produced from TMAsO by reduction. It has been suggested that only 
rats may have relatively high levels of TMAsO in their urine. Rats are also the most 
responsive animal model for arsenic carcinogenesis. A molecule of TMAs(III) possesses no 
ionizable hydroxyl group to limit the ability of this trivalent arsenic species to interact with 
DNA. 
 
1.5.5 Arsenic and Metabolites in Urine 
          Since arsenic is rapidly metabolized and excreted into the urine, total arsenic, inorganic 
arsenic and the sum of arsenic metabolites (inorganic arsenic + MMAs + DMAs) in urine 
have all been used as biomarkers of recent arsenic exposure. In common with other 
biomarkers of arsenic exposure, levels of arsenicals in urine may be a consequence of 
inhalation exposure or ingestion of arsenic from drinking-water, beverages, soil or foodstuffs 
(NRC, 1999). However, in the case of exposure to arsenic compounds of low solubility, e.g. 
GaAs, urinary arsenic will reflect the absorbed dose, but not the inhaled amount (Yamauchi et 
al., 1989). In many older studies, total urinary arsenic was used as a biomarker of recent 
arsenic exposure. However, this is increasingly uncommon because organoarsenicals present 
in substantial amounts in certain foodstuffs are also excreted in urine. For example, the 
practically non-toxic compound arsenobetaine is present in mg/kg levels in seafood and 
excreted mainly unchanged in the urine (Kaise and Fukui 1992; Le et al., 1993, 1994). In 
controlled experiments (e.g. Arbouine and Wilson 1992; Buchet et al., 1994 & 1996), it has 
been found that consumption of seafood (e.g. marine fishes, crustaceans, bivalves, seaweeds) 
by human volunteers is associated with increased total urinary arsenic excretion. Under these 
conditions, assessment of inorganic arsenic exposure using total urinary arsenic would result 
in overestimation of inorganic arsenic exposure. To avoid the potential for overestimation of 
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inorganic arsenic exposure inherent in using total urinary arsenic, most studies now measure 
speciated metabolites in urine and use either inorganic arsenic or the sum of arsenic 
metabolites (inorganic arsenic + MMAs + DMAs) as an index of arsenic exposure. Relatively 
recently it has been found that adding all arsenic metabolites together can give misleading 
results unless a careful diet history is taken and/or seafood consumption is prohibited for 2–3 
days before urine collection (Buchet et al., 1996). There are two reasons for this: First, some 
seafood, especially bivalves, contain the arsenic metabolites MMAs and DMAs, particularly 
DMAs, in fairly high amounts (Velez et al., 1996). Secondly, arsenosugars present in 
seaweeds and some bivalves are extensively metabolized (either by the body itself or by the 
gut microbiota) to DMAs, which is then excreted in urine (Le et al., 1994; Ma and Le, 1998). 
The issue of the extent to which consumption of seafoods and other foods can compromise the 
estimation of inorganic arsenic exposure by the measurement of arsenic and its metabolites in 
urine remains an active area of investigation (Gomez-Caminero et al., 2001). 
 
1.6 Cell Biology 
          The cell is the structural and functional unit of all living organisms. Some organisms 
such as bacteria have only a single cell. Other organisms such as humans have about 100,000 
billion cells. The cell theory, first developed in the 19th century, states that all organisms are 
composed of one or more cells and all fundamental functions of an organism occur within 
cells. Also cells contain the necessary genetic information for regulating cell functions.  
 
1.6.1 Cell Membrane 
          All cells have a plasma membrane, which is a bag that holds the contents of cell. It is a 
bilayer of lipids and proteins that covered by carbohydrates. Thus it separates interior of cell 
from its surroundings. In some cells, outer surface of the plasma membrane are surrounded by 
cell walls such as bacteria, blue-green alga, fungi, and plants. Thus they prevent dehydration 
and survives cell in hypotonic environments. Cell walls contain three dimensional structure of 
cross linked polymers with high molecular weight (Avers, 1978; Thorpr, 1984).  
 
1.6.2 Organelles 
Cells have a set of little organs called organelles that carry out special functions. Some 
of organelles are introduced as follows: 
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 1.6.2.1 Cell Nucleus  
          The nucleus is the control center of the cell. In fact DNA transcription and RNA 
synthesis take places in the nucleus. The components of a nucleus are one or more the 
nucleoli, the nuclear envelope and the chromosomes. Chromosomes act as the bodies which 
house the genes and regulate gene action. The nuclear envelope is a double membrane that 
separates the nuclear interior from surrounding cytoplasm (Avers, 1978; Thorpr, 1984). 
 
1.6.2.2 Ribosomes  
          Ribosomes are the sites of protein synthesis, where RNA transcripts are decoded and 
proteins are synthesized according the coded information. Ribosomes may occur free in the 
cytoplasm or may be bonded to various cellular membranes. There are a large number of 
ribosomes in cell since protein synthesis is important for cell. 
 
1.6.2.3 Mitochondria  
          Mitochondria are organelles with different size and shape that are found in large 
number in plant and animal cells.  Mitochondria are centers for synthesis of high energy ATP 
(adenosine triphosphate) during food breakdown. This process involves a number of 
metabolic pathways including the reactions of the tricarboxylic acid cycle, the oxidation of 
fatty acids and oxidative phosphorylation. Thus mitochondria have a critical role in generating 
energy in the cell.  
 
1.6.2.4 Lysosomes  
          Lysosomes are vesicles that contain a number of hydrolytic enzymes and called 
intracellular digestive systems.  Many different acid hydrolases have been localized in the 
lysosomes that give the cell digesting ability for all the biologically important molecules. 
   
1.6.3 Movements of Substances across Membranes 
         Substances move through membranes selectively in the cell. There are different ways 
which substances cross the membrane barrier. Hydrophobic and small molecules freely 
diffuse trough the membranes along a concentration gradient.  Their diffusion is proportional 
to their solubility in lipid layer of membrane. Other substances those are insoluble in lipid 
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(polar and ionic molecules) move across the membrane by specific carriers that are important 
proteins in membrane cell. These carriers have specific binding site which will bind to 
molecules and transport them as passive or active. In passive transport, the substances move 
in the direction of a concentration gradient but in active transport the molecules move against 
their concentration gradient. The active transport is a process that is entropically unfavourable 
and consumes energy to move the substance against concentration gradient (Avers, 1978). 
 
1.7 Objective of the Present Work 
         The aims of this work divided to two majors studies. (i): Study arsenic metabolites, 
specially trivalent methylated arsenic species (MMAs(III) and DMAs(III)) in urine samples 
collected from Brazilian school children exposed to arsenic-rich drinking water by high 
performance liquid chromatography coupled to inductively coupled plasma mass spectrometry 
(HPLC-ICP-MS) technique while was a joint study with Professor Jörg Matschullat 
(Interdisciplinary Environmental Research Centre, Freiberg University of Mining and 
Technology, Freiberg, Germany) providing the urine samples. The effects of many 
chromatographic parameters such as pH, concentration of ion-pair reagent and buffer, flow 
rate of mobile phase, percentage of added methanol, and also the column temperature were 
investigated to achieve the best separation for arsenic species in the shortest time. (ii) The 
cellular uptake of inorganic arsenic [arsenate, As(V); arsenite, As(III)] and the methylated 
arsenic species monomethylarsonic acid [[MMAs(V)], monomethylarsonous acid 
[MMAs(III)], dimethylarsinic acid [DMAs(V)], dimethylarsinous acid [DMAs(III)], 
trimethylarsenic oxide (TMAsO) were investigated in Chinese hamster ovary (CHO-9) cells, 
human UROtsa (normal human urothelium) cells, HeLa S3 cells, Hep G2 cells, and rat 
hepatocytes (Ra Hep) to determine how arsenic species were taken up by above mentioned 
cell lines. Since the liver is the primary site of arsenic metabolism within the body and is a 
target organ for arsenic carcinogenicity, these type of cells were chosen (Dopp et al., 2005). It 
has been investigated whether the arsenic compounds are bound to membranes or whether 
they are present in the cytosol. For these purposes, the cell membranes were removed by 
osmotic lysis and subsequent centrifugation before the intracellular arsenic concentration was 
measured by ICP-MS. The chemicals were applied at different concentrations (0.1 µM to 10 
mM). Intracellular arsenic concentrations were determined by ICP-MS techniques. In other 
experiment, association and distribution of arsenic substrates with intracellular organelles 
(nucleus, mitochondria, plasma membrane, ribosomes and cytosol) in UROtsa cells has been 
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studied while was investigated in the course of a project (DFG Forschergruppe 415) together 
with a research team of Professor A. W. Rettenmeier/ PD Dr. E. Dopp (Institute of Hygiene 
and Occupational Medicine, University Hospital of Essen) performing the cell exposure 
experiments, and their toxicological evaluation.             
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2 Material and Methods 
 
Caution: Inorganic arsenic compounds have been established as human carcinogens (National 
Research Council Report 1999). Ingestion of inorganic arsenic may cause cancer of the skin, 
urinary bladder, kidney, lung, and liver as well as with disorders of the circulatory and 
nervous system. 
 
2.1 Chemicals and Reagents 
          All reagents used were of the highest purity available and of at least analytical-reagent 
grade. Ultra-pure laboratory water of 18.2 MΩ.cm quality (Seralpur Pro 90 CN, Elga, 
Germany) was used for the preparation and dilution of all reagents, samples and standards.  
Solutions of arsenite (As(III)) and arsenate (As(V)) were prepared from sodium 
arsenite(AsNaO2)  and sodium arsenate (AsHNa2O4.7H2O), respectively. Sodium arsenite was 
obtained from Fluka (Seelze, Germany) while sodium arsenate (AsHNa2O4.7H2O) was 
purchased from Sigma (Taufkirchen, Germany). Monomethylarsonic acid (CH3AsO(OH)2) 
and trimethylarsine oxide ((CH3)3AsO) were purchased from Tri-Chemical Laboratories Inc. 
(Yamanashi, Japan), and dimethylarsinic acid ((CH3)2AsO(OH)) was from Strem (Kehl, 
Germany). Dimethyliodoarsine ((CH3)2AsI) and monomethyldiiodoarsine (CH3AsI2) were 
obtained from Argus Chemicals (Vernio, Italy). Preparation of dilute solutions of these iodide 
arsenicals results in the formation of the related acids, monomethylarsonous acid 
(CH3As(OH)2) and dimethylarsinous acid ((CH3)2AsOH) (Gong et al., 2001; Millar et al., 
1960). Working standard solutions of 0-50 ng.mL-1 were prepared daily from the stock 
solutions by appropriate dilution. However, based on high instability of DMAs(III), solutions 
of this arsenic species were always prepared before each experiment. The reagents used in 
HPLC mobile phase for the RP chromatography were tetrabutylammonium hydroxide from 
Sigma-Aldrich (Steinheim, Germany), malonic acid from Merck (Hohenbrunn, Germany), 
and nitric acid (65%) was obtained from J. T. Baker (USA). HPLC-grade methanol was from 
Merck (Darmstadt, Germany). The reagents used in mobile phase for the cation-exchange 
chromatography were pyridine from sds (France) and formic acid from Fluka (Switzerland).  
 
2.2 Urine Samples 
          At 3 public schools (communities of Galo and Mingu within the township Nova Lima, 
and the village Brumal in the Santa Barbara district), spontaneous urine was sampled from 
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total of 126 children. The children were 7-14 years old (mean 9.8 ± 1.12 years). Several days 
prior to sampling, a coded questionnaire was completed for each child, providing detailed 
information on age, gender, place of birth and period of residence in the observed community, 
breast-feeding, nutrition habits, and health status including previous medical operations and 
dentistry. During sampling, the answers were randomly cross-checked for accuracy. All 
materials were handled consistently with disposable non-powdered latex rubber gloves only. 
An aliquot of fresh urine was kept in acid washed (Nitric acid) PE bottles. All urine samples 
were stored in a cooler while in transport and frozen within 12 h (at -18 oC). This procedure 
complies with standards of the health organisations. Samples were obtained kindly from 
Professor Jörg Matschullat (Interdisciplinary Environmental Research Centre, Freiberg 
University of Mining and Technology, Freiberg, Germany). More information about the area 
where the samples were obtained, and also the map of district, is mentioned on section 3.2.1. 
Urine samples were frozen by placing them in a freezer at our institute, and were stored at -80 
oC. The frozen human urine samples were defrosted at room temperature. Human urine 
samples for analysis were undiluted, and filtered through a 0.45µm pore size filter (Nalgene, 
USA). 20-100 µL of each was injected in to the HPLC column for analysis.  
   
2.3 Cell Lines and Cell Culture Conditions 
Preparation of all cell samples listed below, was performed by the research group of 
PD Dr. E. Dopp at the Institute of Hygiene and Occupational Medicine (under direction of 
Prof. Dr. A. W. Rettenmeier), University Hospital of Essen, and analyzed at Institute for 
Environmental Analysis, University of Duisburg-Essen. Original pictures of the cell lines and 
their information were kindly provided by the research group of PD Dr. E. Dopp.      
 
2.3.1 Human UROtsa Cells 
          The UROtsa cell line was isolated from a primary culture of normal human urothelium 
through immortalization with a construct containing the SV-40 large T-antigen. These cells 
which, kindly provided by Dr. Scott H. Garret, Department of Pathology, School of Medicine 
and Health Sciences, University of North Dakota, USA, were cultured in Dulbecco’s modified 
Eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS), glutamine (20 mg/l) 
and penicillin/streptomycin (100µg/ml) at 37 °C and 5 % CO2. UROtsa cells are adherent cell 
lines that grow as monolayer. Cells were subcultured using trypsin (0.25%) for three minutes.  
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2.3.2 CHO-9 Cells 
          Chinese hamster ovary (CHO-9) cells (obtained from A.T. Natarajan, Leiden, The 
Netherlands) were grown in 25 cm² culture flasks (Greiner) with McCoys 5A medium (Gibco) 
supplemented with 10 % fetal calf serum (Gibco) in the presence of 100 IU/ml penicillin and 
100 µg/ml streptomycin (Gibco) at 37 °C and 5 % CO2. 
 
 
 
 
2.3.3 HeLa S3 Cells 
          HeLa S3 cells were obtained from American Type Culture Collection (ATCC CCL-
2.2). These cells are derived from human cervix adenocarcinoma. For cell culture, they were 
maintained in Ham’s F12K medium supplemented with 10% fetal calf serum (Gibco) in the 
presence of 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco) at 37 °C and 5 % CO2. 
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2.3.4. Hep G2 Cells 
          Hep G2 cells (ATCC, HB 8065) were maintained at 37°C and 5% CO2 in Minimum 
Essential Medium (MEM) with Earle’s BSS and sodium-bicarbonate (CC PRO, Germany) 
supplemented with 10 % heat-inactivated FCS (Gibco), non essential amino acids (0.1 mM), 
sodium-pyruvate (1 mM) and 100 IU/ml penicillin/streptomycin (CC PRO, Germany).    
 
 
 
2.4 Cellular Uptake of Arsenic by Different Cell  Lines 
          In order to investigate and compare the membrane permeability of different cell lines 
against all different arsenic species applied in this study, a wide range of concentration of 
these arsenic substrates from 0.1 µM to 10 mM for an exposure time of 1 h and 24 h were 
used. After incubation, cells were rinsed with phosphate-buffered saline (PBS) and then 
resuspended in 10 ml fresh culture medium. Following cell counting, the cell suspension was 
centrifuged for 5 min at 190 × g and the pellet was resuspended in 10 ml distilled water for at 
least 30 min to lyse the cells. A microscope was used to control the absence of intact cells. 
From this obtained cell solutions two different cell samples were prepared: (a) whole-cell 
extract with membranes and proteins present, and (b) cell-free (membrane removed) extract, 
obtained by osmotic lysis of the whole-cell extract with subsequent centrifugation for 15 min 
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a) Whole-cell extract b) Cell-free extract 
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a) Whole-cell extract b) Cell-free extract 
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Control  Sample  
Incubation Incubation 
at 1700 × g to remove the membranes. The samples were kept frozen at -80 oC until ICP-MS 
analysis. Cellular uptake process is shown in Figure 2.1. 
 
 
 
 
 
 
  
Cells were rinsed with PBS and resuspended in 10 mL fresh culture medium 
 
 
 
 
 
 
 
 
 
After cell counting, the cell suspension was centrifuged for 5 min at 190 × g and the pellet 
was resuspended in 10 mL water to lyse the cell 
 
 
 
 
  
 
  
 
 
 
Figure 2.1 Cellular uptake process 
 
2.4.1 Association of Arsenic with Intracellular Organelles in UROtsa Cells 
          In order to study association of arsenic substrates with intracellular organelles in 
UROtsa cells, differential centrifugation at five steps was performed. Therefore, six different 
samples were prepared for analysis (Figure 2.2).10 × 106 UROtsa cells were incubated with 
the arsenic compounds (5, 500, and 5000 µM) for an exposure time of 1 h and 24 h. 
Following incubation, cells were rinsed with phosphate-buffered saline (PBS) to remove 
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unbound test substances, and subsequently resuspended in 10 ml fresh culture medium. The 
cell suspension was centrifuged for 5 min at 190 × g and the pellet was resuspended in 10 ml 
distilled water for at least 10 min to lyse the cells. A microscope was used to control the 
absence of intact cells. Then, filtered homogenate sample (F sample) obtained by filtering to 
remove clumps of unbroken cells, connective tissue, etc. in this step (Figure 2.2). From this 
cell solution five kinds of samples were prepared by different rate and time of centrifuging 
(see Table 2.1). The precipitate was resuspended to final volume of 2 mL with aqua bidest 
(see Figure 2.2). The samples were stored at -80 oC until ICP-MS analysis. 
 
Table 2.1 Definition of each sample based on differential centrifugation in UROtsa cells 
 
  
 
 Sample Contents 
F Filtered homogenate sample 
N Nuclei 
M Mitochondria, chloroplasts, lysosomes, and peroxisomes 
P Plasma membrane, microsomal fraction, and large polyribosomes 
R Ribosomal subunits, small polyribosomes 
C Cytosol (soluble portion of cytoplasm) 
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Figure 2.2 Differential centrifugation of UROtsa cell lines  
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2.5 Instrumentation 
          Arsenic speciation in urine and cells was quantified by HPLC-ICP-MS based on the 
description of a previously published method (Gong et al., 2000; Geiszinger et al., 1998) 
where an HPLC-HG-AFS detection system was applied. In brief, the mobile phase used for a 
reversed-phase C18 column (Prodigy ODS-3, 150 × 4.6 mm, 3 µm particle size, Phenomenex, 
USA, equipped with a C18 a guard column, 2 cm, same material as analytical column) was as 
follows: 4.7 mM tetrabutylammonium hydroxide + 2mM malonic acid + 4% methanol (pH of 
the mobile phase was adjusted to 5.95 with 25% nitric acid). Measurements of pH were made 
with a pH-meter (pH 211 Microprocessor, Hanna Instruments, Italy) using a combined glass 
electrode. The column was equilibrated with the mobile phase at a flow rate of 0.4 mL/min for 
at least 1.5 h before any sample injection for detection of arsenic species, a PTFE tubing (150 
mm × 0.4 mm) with appropriate fittings was used to connect the outlet of the HPLC column 
directly to the inlet of the ICP-MS (Agilent 7500a, Agilent Technologies, Germany) 
nebulizer. The guard column and the column were heated to 30 oC using a column heater 
(Therma Sphere TM T S-130, Phenomenex, USA). The mobile phase used for a cation-
exchange column (Supelcosil TM LC-SCX, 25 cm × 4.6 mm i.d., 5 µm silica based particles 
with propylsulsonic acid exchange sites, Supelco, USA, equipped with a guard column, 2 cm, 
same material as analytical column) was simply 20 mM pyridine at pH 3.0 adjusted by the 
addition of formic acid. The operation conditions for HPLC and ICP-MS are summarized in 
Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
 
 30
Table 2.2 HPLC-ICP-MS operating conditions 
HPLC 
Column   ODS-3, 150 × 4.6 mm, 3 µm particle size 
Temperature   30 oC 
Mobile phase   4.7 mM tetrabutylammonium hydroxide + 2mM malonic acid +  
   4% methanol (pH 5.95) 
Flow rate   1.5 mL/min 
Injected volume  20 µL 
 
Column   Supelcosil LC-SCX, 150 cm × 4.6 mm, 5 µm particle size 
Temperature   30 oC 
Mobile phase   20 mM pyridine (pH 3.0) 
Flow rate   1.5 mL/min 
Injected volume  20–100 µL 
 
ICP-MS 
Masses   75 (As), 77 (ArCl) 
Integration time  0.1 sec 
RF power   1580 W 
Sample & skimmer cones Ni 
Spray chamber  Double-pass Scott-type 
Sample depth   4.8 mm 
S/C temperature  2 oC   
Plasma gas (Ar)  15 L/min 
Carrier gas (Ar)  0.52 L/min 
Make-up gas (Ar)  0.71 L/min 
Nebulizer   Microflow 
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 3 Results 
 
3.1 Optimization of the HPLC Parameters 
          Optimization of the chromatographic parameters for arsenic was carried out with 
respect to pH, concentration of ion-pair reagent (TBAH), concentration of the buffer (malonic 
acid), percent of methanol in mobile phase, flow rate of mobile phase, and column 
temperature to achieve the best separation for arsenic species in the shortest time. The method 
was then applied to the analysis of biological samples. 
 
3.1.1 Optimization of pH 
          The separation of arsenic species by HPLC is pH-dependent (Le et al., 1996). For 
example, at neutral pH, arsenate (pKa1 = 2.3), MMAs(V) (pKa1 = 3.6), and DMAs(V) (pKa = 
6.2) are present as anions; arsenocholine (AsC) and the tetramethylarsonium ion (Tetra) as 
cations; arsenobetaine (AsB) as a zwitterion; and arsenous acid (pKa1 = 9.3) as an uncharged 
species. In other words, the pH of the mobile phase should have a remarkable effect on the 
retention time of analytes (Dong 2006). Therefore, it is necessary to optimize the pH of 
mobile phase for separating  desired arsenic species. It should be considered that at pH<2 the 
Si-O bonds are subjected to acidic hydrolytic cleavage and at pH>8 the silica structure should 
be dissolved (Dong 2006). Therefore, pH values ranged 4 to 7 were studied. The results are 
shown in Figure 3.1. 
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Figure 3.1 Effect of the pH on the retention time of six arsenic species. ODS column was 
used at 30 oC. The concentration of each species was 10-13.6 ng As/mL. A total volume of 20 
µL was injected. Other experimental conditions: 4.7 mM TBAH, 2 mM malonic acid, 4% 
MeOH, flow rate=1.5 mL/min.  
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3.1.2 Optimization of the Concentration of TBAH 
          Tetrabutylammonium hydroxide (TBAH) is used as an ion-pair reagent. Figure 3.2 
shows the effects of different concentrations of TBAH. An increase in the TBAH 
concentration up to 5.5 mM eliminates peak overlap between dimethylarsinic acid 
(DMAs(V)) and monomethylarsonous acid (MMAs(III)) and also peak overlap between 
arsenate and dimethylarsinous acid (DMAs(III)). As it can be seen in Figure 3.2, this increase 
in the TBAH concentration affects the elution time of all species except arsenite, which is 
independent on changes of TBAH concentration. 
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Figure 3.2 Influence of the TBAH concentration on the retention time of six arsenic species; 
ODS column was used at 30 oC. The concentration of each species was 10-13.6 ng As/mL. A 
total volume of 20 µL was injected. Other experimental conditions: pH 5.95,  2 mM malonic 
acid, 4% MeOH, flow rate=1.5 mL/min. 
 
 
3.1.3 Optimization of the Concentration of Malonic Acid 
          In general buffers in the mobile phase are required for controlling the separations of 
acidic or basic analytes. Buffer concentrations may be used at the different levels. In this 
study, malonic acid was used as a buffer to get a good separation. Figure 3.3 shows the 
influence of malonic acid concentration on retention time of each arsenic species. As can be 
seen in Figure 3.3, an increase in the concentration of malonic acid effectively reduces the 
elution time of arsenic (V).  
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Figure 3.3 Effect of the malonic acid concentration on the retention time of six arsenic 
species; ODS column was used at 30 oC. The concentration of each species was 10-13.6 ng 
As/mL. A total volume of 20 µL was injected. Other experimental conditions: pH 5.95,  4.7 
mM TBAH, 4% MeOH, flow rate=1.5 mL/min 
 
 
3.1.4 Optimization of the Percentage of Methanol 
          It is known that the addition of carbon as methanol to the mobile phase enhances ICP-
MS sensitivity for arsenic (Larsen 1998). Therefore, methanol was added to the aqueous 
chromatographic mobile phase. The methanol content was varied between 0 and 4% (v/v). 
With regard to maximum sensitivity, a concentration of 4% (v/v) methanol was found to be 
optimal amount for separating of investigated arsenic species. Figure 3.4 shows the influence 
of methanol on the retention time of each arsenic species. As it can be seen, addition of 
different percent of methanol does not affect significantly the retention time of each arsenic 
species. But, as it has been mentioned it can affect the signal intensity of each arsenic species, 
which it has been found that the addition of 4% of methanol is optimized amount of methanol.    
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Figure 3.4 Effect of the percent of methanol on the retention time of six arsenic species; ODS 
column was used at 30 oC. The concentration of each species was 10-13.6 ng As/mL. A total 
volume of 20 µL was injected. Other experimental conditions: pH 5.95, 4.7 mM TBAH, 2 
mM malonic acid, flow rate=1.5 mL/min  
 
 
3.1.5 Optimization of Flow Rate and Column Temperature 
          The effects of mobile phase flow rate with a range from 0.8–1.5 mL/min and also of 
column temperature from room temperature up to 60 oC on the retention time of each arsenic 
species were studied. Based on the elution time and also a good separation of each arsenic 
species, the values of 1.5 mL/min and 30 oC for flow rate and the column temperature were 
selected respectively. Figure 3.5 shows the effects of different applied flow rates. As 
expected, increasing the flow rate causes decreasing the elution time of each arsenic species. 
The effect was species dependent, i.e. an increase of flow rate was more effective to decrease 
in the retention time of As(V), DMAs(III), MMAs(V), and DMAs(V). Therefore, a flow rate 
of 1.5 mL/min was selected. Figure 3.6 shows the influences of column temperature on 
retention time of each arsenic species. As it can be seen in Figure 3.6, increasing the column 
temperature does not affect significantly the retention time of each arsenic species. Therefore, 
a column temperature of 30 oC was selected under the optimized conditions. 
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Figure 3.5 Effect of the flow rate on the retention time of six arsenic species; ODS column 
was used at 30 oC. The concentration of each species was 10-13.6 ng As/mL. A total volume 
of 20 µL was injected. Other experimental conditions: pH 5.95, 4.7 mM TBAH, 2 mM 
malonic acid, 4% MeOH 
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Figure 3.6 Influence of the column temperature on the retention time of six arsenic species; 
ODS column was used. The concentration of each species was 10-13.6 ng As/mL. A total 
volume of 20 µL was injected. Other experimental conditions: pH 5.95, 4.7 mM TBAH, 2 
mM malonic acid, 4% MeOH, flow rate=1.5 mL/min 
 
 
 
          The optimum conditions for chromatographic separation and ICP-MS detection of 
arsenic species are summarized in Table 2.2. A chromatogram obtained with reverse phase 
ODS 3µ column for standard solutions of six arsenic species by applying the optimum 
conditions is shown in Figure 3.7. Calibration graphs for each arsenic species are shown in 
Figure A.1. 
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Figure 3.7 A typical HPLC-ICP-MS chromatogram of a mixture of standard solution of six 
arsenic species as labelled obtained with ODS 3µ column. The concentration of each species 
was 10-13.6 ng As/mL. A total volume of 20 µL was injected. 
 
 
3.2 Arsenic Speciation in Urine Samples 
3.2.1 Intention of Study  
          Urine samples from Brazilian children exposed to arsenic-rich drinking water were 
analyzed using HPLC-ICP-MS technique. The urine samples were subjected to speciation 
analysis under the optimum conditions. The identification has been made based on 
chromatographic coelution with standards.  
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Table 3.1 Total arsenic concentration and the distribution of different arsenic species in urine samples of children from Brazil # 
 
Sample                            Concentrationsa of As detected (ng As/mL) ± SD     
  As(V) As(III) MMAs(V) MMAs(III) DMAs(V) DMAs(III) AsB Sumb Totalc Recovery%d 
Urine 261 2.03 ± 0.21 2.27 ± 0.34 3.49 ± 0.48 nd* 6.85 ± 0.89 nd* 0.64 ± 0.06 15.3 ± 1.8 17.7 ± 0.3 86.3 
Urine 254 2.92 ± 0.43 4.86 ± 0.61 4.38 ± 0.43 nd 12.95 ± 1.13 nd 7.99 ± 0.26 33.1 ± 1.8 38.0 ± 0.5 87.1 
Urine 212 4.69 ± 0.61 5.28 ± 0.41 16.23 ± 1.97 2.00 ± 0.16 20.45 ± 1.66 nd nd 48.7 ± 4.3 55.2 ± 0.5 88.1 
Urine 265 1.56 ± 0.24 2.31 ± 0.33 1.47 ± 0.26 0.42 ± 0.06 9.16 ± 0.65  nd nd 14.9 ± 1.3 16.7 ± 0.5 89.3 
Urine 314 2.73 ± 0.40 3.79 ± 0.41 2.27 ± 0.17 0.58 ± 0.07 8.37 ± 0.71 nd nd 17.7 ± 1.7 21.3 ± 0.2 83.3 
Urine 263 1.48 ± 0.26 3.64 ± 0.39 5.71 ± 0.61 0.89 ± 0.08 5.28 ± 0.46 nd 0.69 ± 0.07 17.7 ± 1.5 19.2 ± 0.4 92.1 
Urine 284 3.06 ± 0.55 5.81 ± 0.42 11.69 ± 0.92 0.74 ± 0.08 6.57 ± 0.56 nd 0.71 ± 0.02 28.6 ± 1.6 30.9 ± 0.4 92.5 
Urine 247 2.15 ± 0.39 3.12 ± 0.22 3.25 ± 0.29 0.62 ± 0.06 4.38 ± 0.66 nd nd 13.5 ± 1.5 16.1 ± 0.3 84.0 
Urine 190 1.49 ± 0.21 4.36 ± 0.35 5.01 ± 0.61 0.69 ± 0.06 5.72 ± 0.51 nd nd 17.3 ± 1.7 18.2 ± 0.3 94.9 
Urine 249 2.95 ± 0.42 6.71 ± 0.69 7.36 ± 0.40 1.18 ± 0.13 14.97 ± 0.82 nd 0.76 ± 0.07 33.9 ± 2.4 38.5 ± 0.3 88.1 
Urine 258 2.57 ± 0.36 4.75 ± 0.31 nd 0.59 ± 0.08 8.12 ± 0.49 nd nd 16.0 ± 0.9 19.3 ± 0.2 83.1 
Urine 320 2.45 ± 0.46 5.17 ± 0.26 7.27 ± 0.41 0.97 ± 0.06 8.59 ± 0.46 nd 0.47 ± 0.03 24.5 ± 1.3 31.4 ± 0.2 79.4 
Urine 318 1.69 ± 0.28 nd 2.56 ± 0.29 nd 10.38 ± 0.87 nd nd 14.6 ± 1.3 18.9 ± 0.1 77.4 
Urine 325 2.26 ± 0.23 4.19 ± 0.34 6.58 ± 0.70 0.74 ± 0.05 7.35 ± 0.41 nd 0.94 ± 0.06 22.1 ± 1.4 26.3 ± 0.2 83.9 
Urine 250 3.51 ± 0.36 3.00 ± 0.39 2.86 ± 0.36 0.67 ± 0.07 14.92 ± 0.76 nd nd 25.0 ± 1.7 27.2 ± 0.6 91.8 
 
a The values are given as the average of four repeated injections. b The sum of the concentrations for individual arsenic species. c The total concentration obtained by ICP-MS 
(n=10). d Recovery % is calculated from [sum(species)×100]/total arsenic. # AsC and TMAsO were not detected in any of urine samples. * nd=not detected. 
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3.2.2 Chromatographic Separation of Arsenic Species 
          Due to the different chemical properties of the investigated arsenic compounds, it is not 
readily possible to separate all the investigated arsenic compounds within one 
chromatographic run. A separation technique for anionic arsenic species has been applied 
using an ion pair reverse phase-high performance liquid chromatography coupled to 
inductively coupled plasma mass spectrometry (RP-HPLC-ICP-MS). Six arsenic species 
(arsenite, arsenate, DMAs(V), DMAs(III), MMAs(V), and MMAs(III)) have been separated 
with isocratic elution within less than six minutes. The condition of separation is summarized 
in Table 2.2. Furthermore, cation-exchange chromatography was employed to separate the 
cationic arsenic species. The Supelcosil LC-SCX cation-exchange column allows the 
separation of arsenobetaine (AsB), trimethylarsine oxide (TMAsO), arsenocholine ion (AsC), 
and also tetramethylarsonium cation (Me4As+ = Tetra) with a 20 mM aqueous pyridine 
solution (Geiszinger et al., 1998) at pH 3.0 adjusted by addition of formic acid. The 
identification of the arsenic species present in the urine samples was based on the comparison 
of the retention times with standards and confirmed by spiking experiments for real samples 
as matrices are different as standards alone. A chromatogram obtained with cation exchange 
column for standard solutions of AsB, TMAsO, AsC, and Tetra is shown in Figure 3.8. 
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Figure 3.8 A typical HPLC-ICP-MS chromatogram of a mixture of standard solution of 
arsenic species as labelled obtained with supelcosil LC-SCX cation-exchange column. The 
concentration of each species was 8.5-14.4 ng As/mL. A total volume of 100 µL was injected. 
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3.2.3 Site Description 
          The Iron Quadrangle in the state of Minas Gerais, Brazil, is one of the richest mineral-
bearing regions in the world (Matschullat et al., 2000). Apart from extensive iron ores, 
hydrothermal Au mineralization can be found in Archean greenstone belt formations (Vieira, 
1997; Vieira et al., 1991; Vieira and Simoes, 1992). Active gold mining has been taking place 
in the Nova Lima area since the early 1700’s (Pires et al., 1996). The hydrothermal deposits 
contain several sulfides such as pyrite (FeS2), pyrrhotite (FeS), and arsenopyrite (FeAsS) in 
different proportions. Three major Au deposits can be distinguished within the volcanic 
sediment of the Nova Lima group: Morro Velho in the town of Nova Lima, Raposos and 
Cuiaba. These deposits lie within the district of Nova Lima, 10 km to the south east of the city 
Belo Horizonte, and drain into Rio das Velhas (Figure 3.9A), a tributary to the Rio Sao 
Francisco. In the Nova Lima area, arsenopyrite occurs with 0.8 to 8% in the fresh ore (Fortes 
et al., cit. in Rawlins et al., 1997). Arsenic concentrations in the seriticized sections range 
from several hundred to 2500 mg kg-1 (Sichel and Valenca, 1983). Apart from some small-
scale mining operations, today most of the mining and smelting operations are carried out 
with modern facilities. In the 1990’s, Au production by Morro Velho was around 6 tons 
annually with about 1 million tons of ore (information courtesy of Mineracao Morro Velho 
S.A., 1998; Pires et al., 1996). A control area was chosen within the township of Brumal in 
the Santa Barbara, 60 km east of Belo Horizonte since the major research field was the area of 
Nova Lima. The catchment drains into the Rio da Conceicao (Figure 3.9B), a tributary to Rio 
Doce. On the north west of the Rio da Conceicao, the side opposite to the study catchment, an 
Au mine (Sao Bento) has workd for the past few years and may have resulted in 
contamination of the Conceicao river. According to Fortes et al. (cit. in Rawlins et al., 1997), 
Brumal shows a high potential for a mining related arsenic contamination with 40-70% of 
arsenopyrite in the vein ore bodies. Arsenic concentrations up to several thousand mg kg-1 
(Marques de Souza, 1996) reported in stream sediments of the larger Santa Barbara area. 
However, this area has only recently undergone mineral exploration and data are insufficient. 
Since extensive amounts of arsenopyrite are reported from both the Nova Lima district (Galo 
and Mingu) and the Santa Barbara district (Brumal), a large reservoir is available. In the past, 
an arsenic trioxide factory in the Galo hills may have contributed to the release of arsenic into 
water and also into the soil. Although serious diseases like skin diseases have been observed 
in adults that worked in the old factory, but there are no official health studies. Thus there is 
not available any  health authorities which correlate local arsenic enrichment with related 
public health problems or  in particular the child population. Today, arsenic emissions from 
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the ore processing should be minimum because of modern control facilities. However, due to 
the economic constraints in the mentioned area, people use surface waters not only for fishing 
and gardening but in some cases also as their drinking water. 
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Figure 3.9 The Brazilian State of Mines Gerais and insets showing the area of the Iron 
Quadangle with the districts of A Nova Lima and B Santa Barbara, their drainage pattern and 
the position of abandoned and working mining operations (adapted from Matschullat et al., 
2000) 
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3.2.4 Analyses of Reference Material 
          In order to validate the method, a certified reference material NIES CRM No.18 human 
urine (National Institute for Environmental Studies, Tsukuba, Japan), the only CRM available 
for arsenic species in urine was analyzed. Good agreement was obtained between certified and 
analyzed values for DMAs(V) and AsB in NIES CRM No.18. Table 3.2 shows the certified 
and obtained values for AsB, DMAs(V) and also total arsenic concentrations in the CRM  No. 
18. 
Table 3.2 Certified and obtained values for NIES CRM No. 18 human urine (National 
Institute for Environmental Studies, Tsukuba, Japan) 
 
Element/Species Unit Certified values            Obtained values 
Total arsenic µg/L 137 ± 11                            134.46 ± 0.64a 
DMAs(V) µg/L as As 36 ± 9                                38.05 ± 0.76b 
AsB (Arsenobetaine) µg/L as As 69 ± 12                              71.86 ± 2.08c 
 
aThe total value obtained by ICP-MS. (n=5) 
bThe value is given as the average of four repeated injections using Prodigy ODS 3µ column. 
cThe value is given as the average of four repeated injections using Supelcosil LC-SCX column. 
 
          Arsenic species recovery tests were carried out with both human urine and cell samples, 
by adding standards. The recovery tests for human urine and cell samples were examined by 
adding standards to a sample to increase the concentration between 5 and 40 ng As/mL. The 
average of four recovery tests of the six arsenic species, which were 92-102%, is acceptable 
for the determination of each arsenic species.  
          The chromatographic recoveries were calculated from [sum(species)×100]/total arsenic. 
 
3.2.5 Summary of Analytical Results 
          Table 3.1 summarizes all determined arsenic species of children’s urine samples from 
an arsenic-affected area in Brazil. The reported concentrations are based on the average of 4 
determinations. To validate the method, a certified reference material NIES CRM No.18 
human urine (National Institute for Environmental Studies, Tsukuba, Japan), the only CRM 
available for arsenic species in urine was analyzed. Good agreement was obtained between 
certified and analyzed values for DMAs(V) and AsB in NIES CRM No.18. Table 3.2 shows 
the certified and obtained values for AsB,  DMAs(V) and also total arsenic concentrations in 
the CRM  No. 18. Monomethylarsonous acid [MMAs(III)] was detected in twelve of fifteen 
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samples. Dimethylarsinous acid [DMAs(III)] was not detected at any time, most probably due 
to volatilisation and some oxidation to DMAs(V) (Rabieh et al., publ. in prep.). 
 
3.2.6 Investigation of Monomethylarsonous Acid (MMAs(III)) in Urine 
         It has been reported that trivalent methylated arsenic acids, monomethylarsonous acid 
(MMAs(III)) and dimethylarsinous acid (DMAs(III)), show significantly stronger genotoxic 
effects than the corresponding pentavalent ones and even inorganic arsenic (Dopp et al., 
2004). In one study it was stated that MMAs(III) could supply as an indicator in urine to 
identify individuals with increased susceptibility to toxic and cancer-promoting effects of 
arseniasis (Valenzue la et al., 2005). According to analytical principles, in all the cited reports, 
identification of MMAs(III) and DMAs(III) in urine is based on comparison between HPLC 
retention time of sample and standard. For example when using the Reay and Asher method 
for DMAs(III) synthesis, dimethyldithioarsinic and dimethylthioarsinous acid are produced 
instead of the desired compounds that leading to wrong reference species. 
Dimethylarsinothioic acid was identified based on mass fragmentograms resulted of  HPLC-
ESI-MS not only in the Reay and Asher standard, but also as an arsenosugar metabolite in 
sheep urine (Hansen et al., 2004a,b,c and Martin et al., 2005). However, with regards to these 
results it cannot be excluded that studies using DMPS (2,3- dimercapto-1-propane sulfonate) 
as arsenic-complexing agent also produced S-containing analogues of the analytes. To solve 
this problem, simultaneous HPLC-ICP-MS/ESI-MS analysis will be necessary (Le et al., 
2000a,b and Aposhian et al., 2000). However, in most cases the MMAs(III) and DMAs(III) 
concentrations in urine are too low to be detected by ESI-MS (Hirner 2006). Therefore other 
approaches have been chosen in this study: (i) The retention time interval of MMAs(III) from 
the HPLC run with urine samples from Brazilian children exposed to arsenic-rich drinking 
water was cut off, and then by hydride generation at pH 5 volatilized. The GC separation led 
to clear isolation of MMAsH2 as proven by its mass frangmentogram compared with a library 
standard. The principle of MMAs(III) identification by 2D chromatography is shown in 
Figure 3.10. 
          This states that the analyte is either MMAs(III) (MMAs(V) is separated by HPLC 
separation and not volatilized under the applied pH conditions) or a compound, which 
contains a MMAs(III) group that can be cleaved under the reaction conditions applied. Figure 
3.11 show the chromatograms after hydride generation at pH 5. (ii) Mass of 48 and 50 
monitored as sulphur oxide (48SO, 50SO) during arsenic speciation. In this case, ICP-MS with 
reaction cell (reaction gas: O2, 0.6 mL min-1) was applied (Figure 3.12). The sulphur amount 
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within the retention time interval of MMAs(III) in urine sample was not significant on the 
background of the chromatogram (Rabieh et al., publ. in prep.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Principle of MMAs(III) identification by 2D chromatography and mass 
fragmentation: GC-ICP-MS/EIMS following HPLC fractionation. AsH3 and CH3AsH2 are 
hydride generation (HG) products of As(III) and MMAs(III), respectively (adapted from 
Hirner, 2006) 
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Figure 3.11 ICP-MS chromatogram after hydride generation at pH 5: A the retention time 
interval of MMAs(III) was cut from the HPLC run with urine sample from Brazilian children 
exposed to arsenic-rich drinking water B the retention time interval of MMAs(III) was cut 
from mix of arsenic species  
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Figure 3.12 Chromatogram of an urine sample, and mix of 4 arsenic standards as labelled 
above. 
 
 
3.3 Uptake of Arsenicals by Different Cells 
3.3.1 Cellular Uptake of Inorganic and Organic Arsenic Compounds 
In the present studies, uptake capabilities of different cell lines (UROtsa, CHO-9, Hep 
G2, HeLa S3, and Ra Hep) were investigated. In some cases further experiments, e.g. forced 
uptake by electroporation in CHO cell lines, differential centrifugation in UROtsa cells etc. 
were performed. Parts of obtained data which have already been published are not presented 
here or just briefly described.       
 
3.3.1.1 UROtsa Cells 
          The uptake of the inorganic- and organoarsenic compounds by normal urothelial cell 
lines (UROtsa cells) was tested using concentration from 0.1 µM to 5mM for 1 h. Up to 13% 
of the DMAs(III) substrate in the external medium was taken up by UROtsa cells. This 
highest percentage of DMAs(III) uptake in UROtsa cell was detected at an external 
concentration of 0.1 µM among other exposed external concentrations (0.1 to 10 µM). These 
data suggest that UROtsa cells might be susceptible to relatively low concentration of arsenic 
(0.1 µM). Figure 3.13 shows the percentage of DMAs(III) uptake in UROtsa cell at different 
external concentration after 1 h exposition. Obtained data show, that the percentage uptake of 
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the arsenic substrates for pentavalent arsenic compounds (As(V), MMAs(V), DMAs(V) and 
TMAsO) is negligible, and the percentage range of uptake of other two arsenicals (As(III) and 
MMAs(III)) ranges from 0 to 0.18 percent. Figure 3. 14 shows the percentage of arsenicals 
(except of DMAs(III), which is separately shows on Figure 3.13) uptake in UROtsa cell at 
different external concentration after 1 h exposition. A concentration-dependency was 
observed in this cell line, which reached maximum at 10µM DMAs(III) (Tables A.1-A.3). 
Detected arsenic concentrations in the whole-cell extract and in the membrane-removed cell 
extract indicate no significant differences in the uptake of arsenic species for UROtsa cells 
(Tables A.1-A.3). Therefore, it is concluded that no arsenic substrates bound to the cell 
membrane. The amount of arsenic (ng/106 cells) as well as the percentage of substrate loading 
(%) was measured in whole cell extracts and in membrane-removed cell extracts by 
inductively coupled plasma-mass spectrometry (ICP-MS). Cells were exposed to arsenicals 
for 1 h. 5.0 × 106 cells were analyzed per treatment. Presented values represent means of 
duplicate incubations and five replicate analyses. ND, not detected (<0.02 ng As per 106 
cells). 
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Figure 3.13 Percentage of DMAs(III) uptake in UROtsa cell at different conc. (1 h 
exposition) 
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Figure 3.14 Percentage of arsenicals uptake in UROtsa cell at different conc. (1 h exposition) 
 
 
The uptake of the inorganic and organic arsenic compounds by normal urothelial cell lines 
(UROtsa cells) summarized in Figure 3.15. 
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Figure 3.15 Uptake of arsenicals by UROtsa cells 
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3.3.1.1.1 Association of Arsenic with Intracellular Organelles in UROtsa Cells 
          In order to study association of arsenic substrates with intracellular organelles in 
UROtsa cells, differential centrifugation at five steps was performed. Therefore, six different 
samples were prepared for analysis. Obtained results (Tables A.4-A.10) of differential 
centrifugation indicate that association of arsenic species with +3 oxidation state is higher 
than the +5 species. 
 
3.3.1.1.1.1 Nucleus 
          Percentage of total intracellular As in fraction in the nucleus organelle of UROtsa cell 
lines for an exposure time of 1 h and 24 h is summarized in Figure 3-16. 
 
 
0
2
4
6
8
10
12
Nucleus Nucleus
1h 24h
%
 o
f t
ot
al
 in
tra
ce
llu
la
r A
s 
in
 fr
ac
tio
n As(V)
As(III)
MMAs(V)
MMAs(III)
DMAs(V)
DMAs(III)
TMAsO
 
 
Figure 3.16 Percentage of total intracellular As in fraction in the nucleus of UROtsa cell 
(exp.time:1h & 24h) 
 
          As it can be easily seen in the Figure 3.16, uptake capabilities of all arsenic species 
(except TMAsO) are dependent on exposure time. Up to 10% of the DMAs(III) substrate in 
the external medium was taken up by nucleus at 1 h exposition. Results show, that uptake of 
this compound decrease to 5% for an exposure time of 24h. It’s interesting that among the all 
arsenicals, only behaviour of As(III) is different compared to others. That means increasing of 
incubation time from 1 h to 24 h increase the uptake capability by the factor of 3.3. The 
species As(III), MMAs(V), and MMAs(III) were taken up to a slightly lower degree for an 
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exposure time of 24 h compare to 1 h exposition. A low amount of As(V) was taken up at 1 h 
exposition, which was not detected as the exposure time increased to 24 h. 
 Figure 3.17 shows the amount of  detected arsenic in ng per 106 cells in the nucleus 
organelle of UROtsa cell lines for an exposure time of 1 h and 24 h. The results show that the 
detected arsenic concentrations of trivalent species As(III), MMAs(III), and DMAs(III) at the 
exposure time of 1 h are significantly higher than those at 24 h exposition. Among all tested 
arsenic species detected DMAs(III) concentration is higher than other species with the amount 
of 5.6 ng per 106 cells for an exposure time of 1 h. Longer exposure time up to 24 h has a 
different effect on the amount of detected arsenic species. For example, results show that the 
detected arsenic concentration of pentavalent species MMAs(V), DMAs(V), and TMAsO at 
the exposure time of 24 h is 2-3 times higher than those at 1 h exposition. In other hand, the 
detected arsenic concentration of trivalent species As(III), MMAs(III), and DMAs(III) at the 
exposure time of 1 h is significantly higher than those at 24 h exposition.  
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Figure 3.17 Detected arsenic concentration (ng per 106 cells) in the nucleus of UROtsa cell 
(exp.time:1h & 24h) 
 
3.3.1.1.1.2 Mitochondria 
 Percentage of total intracellular As in fraction in the mitochondria organelle of UROtsa 
cell lines for an exposure time of 1 h and 24 h is summarized in Figure 3-18. 
 
 
 
Results 
 
 51
0
1
2
3
4
5
6
7
Mitochondria Mitochondria
1h 24h
%
 o
f t
ot
al
 in
tra
ce
llu
la
r A
s 
in
 fr
ac
tio
n
As(V)
As(III)
MMAs(V)
MMAs(III)
DMAs(V)
DMAs(III)
TMAsO
 
 
 Figure 3.18 Percentage of total intracellular As in fraction in the mitochondria of UROtsa 
cell (exp.time:1h & 24h) 
 
Results show that the uptake capabilities of all arsenic species (with the exception of 
TMAsO) are dependent on exposure time. The effect of exposure time for some species is 
significantly higher than others. Among them, the percentage of As(V) from 0 at exposure 
time of 1 h becomes 6.6% at 24 h exposition, which is the highest percent of uptake among 
the other tested arsenic species. The amount of As(III) and DMAs(V) species were taken up 
for an exposure time of 24 h  almost 5 times more than those at 1 h exposition. For MMAs(V) 
the effect of longer exposition is different i.e. for an exposure time of 24 h the percentage of 
arsenic was decreased from 1.6% (at 1 h exposition) to 0.8%.  
As it can be seen from the Figure 3.18, TMAsO is independent of exposure time, and 
the percent of TMAsO which was taken up, was the same for an exposure time of 1 h and also 
24 h. 
Figure 3.19 shows the amount of  detected arsenic in ng per 106 cells in the 
mitochondria organelle of UROtsa cell lines for an exposure time of 1 h and 24 h. The results 
show that the detected arsenic concentration of pentavalent species As(V), MMAs(V), 
DMAs(V), and TMAsO at the exposure time of 24 h is higher than those at 1 h exposition. 
The highest detected arsenic was obtained for DMAs(V) at the exposure time of 24 h, which 
was 2.32 ng arsenic per 106 cells.  
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Figure 3.19 Detected arsenic concentration (ng per 106 cells) in the mitochondria of UROtsa 
cell (exp.time:1h & 24h) 
 
Detected arsenic concentration of trivalent species As(III), MMAs(III), and DMAs(III) at the 
exposure time of 1 h is higher than those at 24 h exposition. 
 
3.3.1.1.1.3 Plasma Membrane 
Percentage of total intracellular As in fraction in the plasma membrane of UROtsa cell 
lines for an exposure time of 1 h and 24 h is summarized in Figure 3-20.  
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Figure 3.20 Percentage of total intracellular As in fraction in the plasma membrane of 
UROtsa cell (exp.time:1h & 24h) 
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As it can be seen in the Figure 3.20, uptake capabilities of all arsenic species are 
dependent on exposure time. Increasing of incubation time from 1 h to 24 h increase the 
uptake capability of all tested arsenic compounds with the exception of MMAs(III) and 
DMAs(V). At the exposure time of 1 h no arsenate substrate was detected, whereas up to 14% 
of it was detected at the exposure time of 24 h. This amount was the highest amount which 
was taken up among of all tested arsenic compounds. The amount of As(III) was taken up for 
an exposure time of 24 h almost 5 times more than that at 1 h exposition. Monomethylarsinic 
acid and dimethylarsinous acid were taken up to a slightly higher degree for an exposure time 
of 24 h compare to 1 h exposition, while for DMAs(V) and MMAs(III) were vice versa. The 
amount of TMAsO was taken up in the plasma membrane for an exposure time of 24 h almost 
three times more than that at 1 h exposition. 
Figure 3.21 shows the amount of  detected arsenic in ng per 106 cells in the plasma 
membrane of UROtsa cell lines for an exposure time of 1 h and 24 h. The highest detected 
arsenic was obtained for MMAs(III) at the exposure time of 1 h, which was 12.06 ng arsenic 
per 106 cells. The results show that the detected arsenic concentrations of pentavalent species 
As(V), MMAs(V), DMAs(V), and TMAsO at the exposure time of 24 h are higher than those 
at 1 h exposition, while the detected arsenic concentrations of trivalent species As(III), 
MMAs(III), and DMAs(III) at the exposure time of 1 h were higher than those at 24 h 
exposition. Among all tested arsenic species, As(V) was not detected at the exposure time of 1 
h. 
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Figure 3.21 Detected arsenic concentration (ng per 106 cells) in the plasma membrane of 
UROtsa cell (exp.time:1h & 24h) 
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3.3.1.1.1.4 Ribosomes 
Percentage of total intracellular As in fraction in the ribosomal subunits of UROtsa cell 
lines for an exposure time of 1 h and 24 h is summarized in Figure 3.22.  
 
0
2
4
6
8
10
12
Ribosomes Ribosomes
1h 24h
%
 o
f t
ot
al
 in
tra
ce
llu
la
r A
s 
in
 fr
ac
tio
n
As(V)
As(III)
MMAs(V)
MMAs(III)
DMAs(V)
DMAs(III)
TMAsO
 
 
Figure 3.22 Percentage of total intracellular As in fraction in the ribosomal subunits of 
UROtsa cell (exp.time:1h & 24h) 
 
As it can be seen in the Figure 3.22, uptake capabilities of all arsenic species are 
dependent on exposure time. 10.7% of As(III) and MMAs(III) species were taken up at the 
exposure time of 24 h. This amount was the highest percentage of uptake among the all tested 
arsenic compounds. The amount of As(V) was taken up for an exposure time of 24 h five 
times more than that at 1 h exposition. As(III) was taken up to a slightly higher degree for an 
exposure time of 24 h compare to 1 h exposition. But results show that MMAs(V) and 
DMAs(V) were taken up to a slightly lower degree for an exposure time of 24 h compared to 
1 h exposition. Percentage of DMAs(III) uptake at the exposure time of 24 h decreased 
slightly from 9% to 7.2 percent at 1 h exposition. In other hand, TMAsO was taken up at the 
exposure time of 24 h more than two times higher than that at 1 h exposition. 
Figure 3.23 shows the amount of  detected arsenic in ng per 106 cells in the ribosomal 
subunits of UROtsa cell lines for an exposure time of 1 h and 24 h. The highest detected 
arsenic was obtained for As(III) at the exposure time of 1 h, which was 7.77 ng arsenic per 
106 cells. 
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Figure 3.23 Detected arsenic concentration (ng per 106 cells) in the ribosomal subunits of 
UROtsa cell (exp.time:1h & 24h) 
 
The results show that the detected arsenic concentrations of pentavalent species As(V), 
MMAs(V), DMAs(V), and TMAsO at the exposure time of 24 h are higher than those at 1 h 
exposition, which the highest detected arsenic was obtained by MMAs(V) with almost 5 ng 
arsenic per 106 cells among the pentavalent species. MMAs(III) was taken up to a slightly 
higher degree for an exposure time of 24 h compare to 1 h exposition, whereas the uptake of 
DMAs(III) decreased significantly at the exposure time of 24 h.  
Subcellular distribution of different arsenic species in UROtsa cells for an exposure 
time of 1 h and 24 h are shown in Figures 3.24 and 3.25. 
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Figure 3.24 Subcellular distribution of different arsenic species in UROtsa cells (exposure 
time: 1 h) 
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Exposure time: 24 h
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Figure 3.25 Subcellular distribution of different arsenic species in UROtsa cells (exposure 
time: 24 h) 
 
3.3.1.2 CHO Cells 
          The uptake of the inorganic and organic arsenic compounds by CHO cell lines was 
tested using concentrations from 0.1 µM to 1 mM for 1 h. Most of the results from this study 
has already been published (Dopp et al., 2005). Obtained data is given in appendix (Tables 
A.11-A.13). The amount of arsenic (ng/106 cells) and also the percentage of substrate loading 
(%) was measured in whole-cell extracts and in cell-free (membrane removed) extracts by 
inductively coupled plasma-mass spectrometry (ICP-MS). Cells were exposed to arsenic 
compounds for 1 h. 8.8 × 106 cells were analyzed per treatment. Presented values represent 
means of duplicate incubations and five replicate analyses (mean %RSD = 3.3%). ND, not 
detected (<0.02 ng As per 106 cells) (Tables A.11-A.13).  
 
          Percentage of arsenate/arsenite, methylated pentavalent, and methylated trivalent 
arsenic species uptake in CHO-9 cell lines for an exposure time of 1 h is summarized in 
Figures 3.26-3.28.  
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Figure 3.26 Percentage of total intracellular arsenic in the CHO-9 cell lines (exp. Time:1h) 
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Figure 3.27 Percentage of total intracellular arsenic in the CHO-9 cell lines (exp. Time:1h) 
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Figure 3.28 Percentage of total intracellular arsenic in the CHO-9 cell lines (exp. Time:1h) 
(note: external conc. of 0.1 & 5 µM of MMAs(III) and also 25 & 50 µM of DMAs(III) have 
been not investigated). 
 
 
3.3.1.3 Hep G2 Cells 
          The uptake of the inorganic and organic arsenic compounds by Hep G2 cells was tested 
using concentrations from 0.5 µM to 5 mM for 1 h. Most of the results from this study have 
already been published (Dopp et al., 2005). Obtained data is given in appendix (Tables A.14-
A.16). The amount of arsenic (ng/106 cells) and also the percentage of substrate loading (%) 
was measured in whole-cell extracts and in cell-free (membrane removed) extracts by 
inductively coupled plasma-mass spectrometry (ICP-MS). Cells were exposed to different 
arsenic compounds for 1 h. 3.3 × 106 cells were analyzed per treatment. Presented values 
represent means of duplicate incubations and five replicate analyses (mean %RSD = 3.3%). 
ND, not detected (<0.02 ng As per 106 cells) (Tables A14-A16).  
          Comparison of obtained data between hepatoma cells (Hep G2) and UROtsa cells 
reveal the following points: 
 
• DMAs(III) was best taken up by both cell types follow by MMAs(III) and As(III) 
• A concentration-dependency was observed for all arsenic compounds 
• Arsenic compounds did not appear to associate with the cell membrane of both cells 
•  With the exception of DMAs(III), intracellular arsenic concentrations for As(III), 
As(V), MMAs(III), and DMAs(V) were 2-8 fold higher in Hep G2 than in UROtsa 
cells. 
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The uptake of the inorganic and organic arsenic compounds by Hep G2 Cells summarized in 
Figure 3.29. 
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Figure 3.29 Uptake of arsenicals by Hep G2 cells 
3.3.1.4 HeLa S3 Cells 
HeLa S3 has been selected because it is an established cellular system for testing types 
of cell death and physiologic distributions. The uptake of the inorganic and organic arsenic 
compounds by HeLa S3 cells was tested using concentrations from 0.5 µM to 5 mM for 1 h. 
The obtained results are summarized in Tables A.17–A.18.   
 As it can be seen from the obtained results, up to 1.2% of the MMAs(III) substrate in 
the external medium was taken up by HeLa S3 cells. This highest percentage of MMAs(III) 
uptake in HeLa S3 cell was detected at an external concentration of 0.5 µM among other 
exposed external concentrations (0.5 to 10 µM). These data suggest that HeLa S3 cells might 
be susceptible to relatively low concentration of arsenic (0.5 µM). Detected arsenic 
concentrations in the whole-cell extract and in the cell free (membrane removed) extract 
indicate no significant differences in the uptake of arsenic species for HeLa S3 cells (Tables 
A.17-A.18). Therefore, it is concluded that no arsenic substrates bound to the cell membrane. 
Obtained data indicate that with the exception of MMAs(III) and DMAs(III), the percentage 
of other tested arsenic substrates in the external medium, which were taken up by HeLa S3 
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was zero. Almost 0.5% of DMAs(III) substrate in the external medium was taken up by HeLa 
S3 cells. This amount was almost same for all exposed external concentrations range (0.5 to 
10 µM). The uptake of the inorganic and organic arsenic compounds by HeLa S3 cells 
summarized in Figure 3.30. 
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Figure 3.30 Uptake of arsenicals by HeLa S3 cells 
 3.3.1.5 Ra Hep Cells 
          Rat hepatocytes (Ra Hep) cell was the last cell type which has been studied. The uptake 
of the inorganic and organic arsenic compounds by rat hepatocytes (Ra Hep) cells was tested 
using concentrations from 0.5 µM to 5 mM for 1 h. The obtained results are summarized in 
Tables A.19–A.20.  
          As it can be seen from the obtained results, up to 0.75% of the MMAs(III) substrate in 
the external medium was taken up by rat hepatocytes (Ra Hep) cells. This highest percentage 
of MMAs(III) uptake in Ra Hep cell was detected at an external concentration of 0.5 µM 
among other exposed external concentrations (0.5 to 500 µM). These data suggest that Ra Hep 
cells might be susceptible to relatively low concentration of arsenic (0.5 µM). Detected 
arsenic concentrations in the whole-cell extract and in the cell free (membrane removed) 
extract indicate no significant differences in the uptake of arsenic species for Ra Hep cells 
(Tables A.19-A.20). Therefore, it is concluded that no arsenic substrates bound to the cell 
membrane. Obtained data indicate that the percentage of pentavalent tested arsenic substrates 
in the external medium, which were taken up by rat hepatocytes (Ra Hep) was zero. Almost 
0.4% of As(III) and DMAs(III) substrates in the external medium was taken up by Ra Hep 
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cells. The uptake of the inorganic and organic arsenic compounds by rat hepatocytes (Ra Hep) 
cells summarized in Figure 3.31. 
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Figure 3.31 Uptake of arsenicals by Ra Hep cells 
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4 Discussion 
Humans are exposed to arsenic and their organic metabolites mostly via food, water, 
and less via air. Following uptake, inorganic arsenic undergoes biotransformation to mono- 
and dimethylated metabolites (Dopp et al., 2004). Chronic arsenic exposure increases risk for 
the development of diabetes, vascular disease, and cancers of the skin, lung, kidney, and 
bladder (Chiou et al., 1995).Therefore, the following studies were performed: 
1. Study arsenic metabolites, specially trivalent methylated arsenic species (MMAs(III) and 
DMAs(III)) in urine samples collected from Brazilian school children exposed to arsenic-rich 
drinking water by high performance liquid chromatography coupled to inductively coupled 
plasma mass spectrometry (HPLC-ICP-MS) technique. The effects of many chromatographic 
parameters such as pH, concentration of ion-pair reagent and buffer, flow rate of mobile 
phase, percentage of added methanol, and also the column temperature were investigated to 
achieve the best separation for arsenic species in the shortest time. In the results section these 
effects have also been described. 
2. The cellular uptake of inorganic arsenic [arsenate, As(V); arsenite, As(III)] and the 
methylated arsenic species monomethylarsonic acid [MMAs(V)], monomethylarsonous acid 
[MMAs(III)], dimethylarsinic acid [DMAs(V)], dimethylarsinous acid [DMAs(III)], 
trimethylarsenic oxide [TMAsO] were investigated in Chinese hamster ovary (CHO-9) cells, 
human UROtsa (normal human urothelium) cells, HeLa S3 cells, Hep G2 cells, and rat 
hepatocytes (Ra Hep), to determine how arsenic species were taken up by above mentioned 
cell lines. Since the liver is the primary site of arsenic metabolism within the body and is a 
target organ for arsenic carcinogenicity, these type of cells were chosen (Dopp et al., 2005). It 
has been investigated whether the arsenic compounds are bound to membranes or whether 
they are present in the cytosol. For these purposes, the cell membranes removed by osmotic 
lysis and subsequent centrifugation before the intracellular arsenic concentration were 
measured by ICP-MS. The chemicals were applied at different concentrations (0.1 µM to 10 
mM). Intracellular arsenic concentrations were determined by ICP-MS techniques. 
3. In the other experiment, association and distribution of arsenic substrates with intracellular 
organelles (nucleus, mitochondria, plasma membrane, ribosomes and cytosol) in UROtsa cells 
has been studied. For these investigations, differential centrifugation at five steps is 
considered. Therefore, six different samples were prepared for analysis (see chapter 2, Figure 
2.2). 
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4.1 Speciation of Arsenic in Urine Samples  
          The urine samples were subjected to speciation analysis under the optimum conditions. 
Obtained results show that, in addition to the inorganic arsenic species (arsenite and arsenate), 
organoarsenic species also were detected. In the following the obtained results will be 
discussed in the light of the relevant literature (see also Table 4.1).              
 
4.2 Trivalent Methylated Arsenic Acids 
          The determination of trivalent arsenic species (MMAs(III) and DMAs(III)) are 
important because it has been demonstrated that these metabolites exhibit significantly 
stronger genotoxic effects than the corresponding pentavalent ones and even inorganic arsenic 
(Hirner 2006).   
 
4.2.1 Dimethylarsinous Acid (DMAs(III)) 
          In a simple experiment, it has been shown that DMAs(III) is very unstable: After 
running mixture of arsenic species including DMAs(III) through HPLC-ICP-MS (Figure 3.5), 
it has been kept frozen (-25 oC) for 24 h. Then, after this period of time, this mixture of 
arsenic species was analyzed again, which there was no corresponding peak for DMAs(III). It 
has already been shown from the obtained results (Table 3.1) that DMAs(III) was not detected 
at any time most probably due to volatilisation and oxidation to DMAs(V). In one study both 
DMAs(III) and MMAs(III) have been reported in urine of some humans exposed to inorganic 
arsenic through their drinking water in West Bengal, India (Mandal et al., 2001). The authors, 
reported the range of 4-21% of DMAs(III) of the total urinary arsenic, where the samples 
were analyzed ~2 months after collecting. In an other study, Mandal et al. (2004) reported up 
to 21.9 µg/L DMAs(III) (13%) of the total urinary arsenic, where the sample was analyzed ~2 
months after collecting. Thus it seems to be unrealistic to report DMAs(III) in over 2 month 
old samples from West Bengal (Hirner 2006) when the stability of this species has been 
reported not to exceed one day (Gong et al., 2001). Other studies reported relatively high 
amount of DMAs(III) in urine samples from individuals chronically exposed to inorganic 
arsenic by consumptions of drinking water containing this metalloid, in these cases however, 
the samples have been analysed within 5-6 h of collection. Del Razo et al. (2001) reported the 
range of 6-31% of DMAs(III) of the total urinary DMAs. The major metabolite, DMAs(III), 
represented 49% of total urinary arsenic, reported by Valenzuela et al. (2005) from the urine 
samples chronically exposed to high inorganic arsenic from an area located in the central part 
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of Mexico. On the other hand, these studies were also criticized because of not strictly 
differentiating between free and glutathione-complexed DMAs(III) (Francesconi and 
Kuehnelt, 2004). 
 
4.2.2 Monomethylarsonous Acid (MMAs(III)) 
          Up to 5% of monomethylarsonous acid (MMAs(III)) of the sum urinary metabolites has 
been detected in urine samples collected from Brazilian school children exposed to arsenic-
rich drinking water (Table 3.1). The percentage of trivalent methylated arsenic metabolites 
obtained here were typically comparable or lower than those reported in the literature. This 
might be due to malnutrition of the population that was being studied. MMAs(III) and 
DMAs(III) are normally bound to proteins and glutathione in the body because the trivalent 
arsenic species have a high affinity for thiol group in these molecules (Cullen et al., 1989; 
Zakharyan et al., 1999; Thompson, 1993 and Styblo, et al., 1995). When dimercaptopropane 
sulfonate (DMPS) is administered, those MMAs(III) and DMAs(III) species presumably were 
chelated to the excess DMPS and excreted into the urine (Aposhian et al., 1997 and Aposhian, 
1983). But here, all urine samples collected without any prechemical treatment. Due to 
malnutrition, the concerned population lacked proteins and the trimethylated arsenicals were 
not bound fully to proteins in vivo. Hence, obtained results here might be at the lower side 
compared to those of Aposhian et al. (2000b). Many studies reported the percentage of 
MMAs(III) as different ranges in urine. Aposhian et al. (2000b) reported the amount of 11 and 
7% for MMAs(III) of the urinary arsenic from the subjects in Romania who have been 
exposed to 84 or 161 µg of As/L in their drinking water. The range of 4 to 9% of MMAs(III) 
of the total urinary methyl arsenic has been reported by Del Razo et al. (2001) in the urine 
samples from individuals chronically exposed to inorganic arsenic by consumptions of 
drinking water containing this metalloid in the central Mexico. The range of 2 to 5% of 
MMAs(III) have found in the human urine samples of an area in West Bengal, India (Mandal 
et al., 2001). Le et al. (2000a) reported a high amount of MMAs(III) (240 µg/L) in human 
urine of Inner Mongolia. 
          In all reports, identification of  MMAs(III) and DMAs(III) in urine is only based on 
comparison between HPLC retention time of sample and standard. While using the Reay and 
Asher method for DMAs(III) synthesis, dimethyldithioarsinic and dimethylthioarsinous acid 
are produced instead of the desired compounds, that leading to wrong reference species 
(Hirner, 2006). To try to solve this problem, simultaneous HPLC-ICP-MS/ESI-MS analysis 
will be necessary. However, obtained results here show very low concentration of MMAs(III) 
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(maximum concentration was 2 µg/L) in urine samples, and can not to be detected by ESI-
MS. Therefore, another approaches (Hirner 2006) has been chosen: (i) The retention time 
interval of MMAs(III) from the HPLC run with urine samples from Brazilian children 
exposed to arsenic-rich drinking water was cut off and then by hydride generation at pH 5 
volatilized (Rabieh et al., publ. in prep.). The GC separation led to obvious isolation of 
MMAsH2 as proved by its mass fragmentogram compared to a library standard (see Figures 
3.8-3.9). (ii) Monitoring mass of 48 and 50 as sulphur oxide (48SO, 50SO) during arsenic 
speciation. In this case, ICP-MS with reaction cell (reaction gas: O2, 0.6 mL min-1) was 
applied (Figure 3.10). The amount of sulphur on the background of the chromatogram within 
the retention time interval of MMAs(III) in urine sample was negligible. 
4.2.3 Other Metabolites of Arsenic 
          As it can be seen from the Table 3.1 different range of other arsenic metabolites have 
been detected in this work. Percentage of DMAs(V) in the range of 27 – 55% (except one 
sample which was 21%) was detected in the urine samples in this study, which was 
comparable to those previously reported in the other studies. This metabolite was the major 
arsenic compound found in the urine. Mandal et al. (2001) reported the range of 44 – 74% of 
DMAs(V) of the total urinary arsenic in the urine samples from West Bengal, India. The range 
of 26 – 58% of DMAs(V) was detected in the urine samples from Promyelocytic Leukemia 
Patients collected 24 h after the injection of As(III) (Wang et al., 2004). Other studies also 
reported similar concentrations stating that DMAs(V) was the major arsenic metabolite which 
is excreted in the urine (Le et al., 2000a,b; Francesconi et al., 2002; Suzuki 2005; Feldmann et 
al., 2000; Stoeppler and Vahter 1994; Hakala and Pyy 1995; Del Razo et al., 2001; Meza et 
al., 2004). 
          Arsenite has been obtained in this study in the range of 9 to 19% (except one sample 
which has a high amount of 24%). Different range for arsenite has been reported in the 
literature: Le et al. (2000a) reported relatively high amount of arsenite ranging 17 to 32% of 
the total arsenic from the urine samples in Inner Mongolia, China. The range of 8-14 % has 
been reported in one study (Mandal et al., 2001) in the human urine samples of the areas in 
West Bengal, India. Del Razo et al. (2001) reported the range of 8 to 19% of the total arsenic 
in urine samples from the central Mexico. The range of 22 – 36% of arsenite was detected in 
the urine samples from Acute Promyelocytic Leukemia Patients collected 24 h after the 
injection of arsenic trioxide (Wang et al., 2004). Meza et al. (2004) reported 16 to 30% of 
arsenite of the total urinary arsenic in the urine samples in Sonora, Mexico. In another study 
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of a population in northern Argentina, children were found to have a substantially high 
percentage of inorganic arsenic (50%) in their urine samples (Concha et al., 1998). 
          Arsenate in the range of 7 to 13% was detected here. Mandal et al. (2001) reported 2-
13% of arsenate in their study. The range of 7 to 11% was detected by Del Razo et al. (2001) 
in the human urine samples from central Mexico.Valenzuela et al. (2005) reported 9% of 
As(V) of the total arsenic in urine samples from Zimapan in the state of Hidalgo, in the central 
part of Mexico. MMAs(V) is obtained ranging 8.8 to 29% with the exception of one sample 
contains 37% of the total arsenic which was comparable (and also for some of the samples 
higher) to those previously reported in the literature. Le et al. (2000a) reported the range of 
11-21% of this metabolite in the urine samples in Inner Mongolia, China. 8 to 11% of 
MMAs(V) has been reported by Mandal et al. (2001) in the urine samples of areas in West 
Bengal, India. Del Razo et al. (2001) reported 9 to 22% of this metabolite in the urine samples 
from Zimapan in central Mexico. The range of 14 to 32% of MMAs(V) was obtained in the 
urine samples of APL patients collected 24 h after the injection of arsenic trioxide (Wang et 
al., 2004). 
          Trimethylarsine oxide (TMAsO) is not detected at any time in this study. TMAsO has 
been identified as a metabolite in bacterial systems. Little is known about TMAsO in humans. 
Failure to observe TMAsO suggests that either its concentration in urine is below the 
detection limit of the method or it is further metabolized to trimethylarsine and subsequently 
exhaled into the breath as it is a volatile species (Le et al., 2000a). Francesconi et al, (2002) 
reported a very low amount of this metabolite (0.5%) in human urine after ingestion of an 
arsenosugar. Sur and Dunemann (2004) reported also a low amount of this species (TMAsO) 
up to    % in human urine after consumption of seafood.                                  
          Tetramethylarsenium ion (Tetra) and Arsenocholine (AsC) metabolites have been not 
detected in any urine samples studied here. Arsenobetaine (AsB) has been detected at low 
range of 2 to 4% (except one sample with 21%) in some samples. This metabolite is the major 
constituent in seafood products, which excreted unchanged in the urine (Le et al., 1994). 
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Table 4.1 Arsenic species analyzed in human urine 
 
  
Percentage of As detected in human urine samples 
 
As(V) 
 
As(III) 
 
MMAs(V) 
 
MMAs(III)
 
DMAs(V) 
 
DMAs(III) 
 
TMAsO 
 
AsB 
 
Ref 
 
2–13 8–14 8–11 2–5 44–74 4–21 – – Mandal et al., 2001 
10.1 11.3 10.5 6.6 47.5 13 – 1 Mandal et al., 2004 
7–11 8–19 9–22 4–9 7–61 6–31 – – Del Razo et al., 2001 
7–13 9–19 8–29 up to 5 27–55 ND ND 2–4 This study 
9 9 3 7 24 49 – – Valenzuela et al., 2005 
– – 13–14 7–11 – – – – Aposhian et al., 2000b 
1–5 22–36 14–32 1–2 26–58 0.1–0.6 – – Wang et al., 2004 
– – – – 11–21 (µg L-1) – – 18–137 (µg L-1) Moldovan et al., 1998 
1–5 (µg L-1) 4–9 (µg L-1) 2–4 (µg L-1) – 16–26 (µg L-1) – – – Meza et al., 2005 
2–3 16–30 7–14 – 40–71 – – – Meza et al., 2004 
ND 17–32 11–21 up to 40 15.3–61.2  up to 12 – – Le et al., 2000a 
– – – – 67 – 0.5 – Francesconi et al., 2002 
0.3–15 0.4–23 0.2–21 – 1–69 – – 13–91 Ritsema et al., 1998 
0.7–9.3 0.3–12.8 0.2–9.3 – 6–53 – – – Hakala and Pyy, 1995 
    –: not reported 
ND: not detected 
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Ritsema et al, (1998) reported AsB as the main constituent of the total arsenic present in the 
urine samples of volunteer who consumed a portion (250 g) of tuna fish, ranging from 88% 
after 12 h to 58% after 94 h.    
           
4.3 Uptake Experiments 
4.3.1 Comparison Between Fibroblasts and Hepatoma Cells  
          Monomethylarsonous acid (MMAs(III)) and dimethylarsinous acid (DMAs(III)) have 
been reported to be highly toxic in mammalian cells (Cohen et al., 2002; Styblo et al., 2000, 
2002) and genotoxic (Mass et al., 2001; Nesnow et al., 2002). The reason for the high toxicity 
of methylated trivalent arsenicals has not been adequately explained, except that methylated 
trivalent arsenicals exert genotoxicity via reactive oxygen species (Nesnow et al., 2002). The 
trivalent methylated arsenic metabolite DMAs(III) was the most membrane-permeable species 
whereas up to 16% uptake by CHO-9 cells from the external medium was observed, when the 
cells were cultured with 0.5 µM DMAs(III), and the uptake of As(III) was lower, amounting 
to 3.8% of initial substrate loading. As shown in Tables A.11-A.13, the highest arsenic uptake 
was mostly detectable at relatively low concentrations (DMAs(III): 0.5 µM, As(III): 1.0 µM) 
and this percentage decreases with increasing arsenic concentrations in the external medium. 
It might be that a defence mechanism exists i.e. the extrusion of As(III) out of the cells and 
the prevention of an uptake at higher concentrations.  
          The uptake capability of DMAs(III) by Hep G2 cells was much lower (~4.5% from the 
external medium at 10-fold higher concentrations i.e. at 5 µM) compared to CHO-9 cell lines. 
An intensive comparison between these two cell types has been discussed in a published paper 
(Dopp et al., 2005).  
 
4.3.2 UROtsa Cell Line 
4.3.2.1 Cellular Uptake 
          The pentavalent arsenic species were not taken up by UROtsa cell lines at different 
applied concentrations (0.5 µM to 5 mM). The trivalent methylated arsenic derivative 
DMAs(III) was the most membrane-permeable species whereas up to 13.3% uptake by 
UROtsa cells from the external medium was shown, when the cells were cultured with 0.1 µM 
DMAs(III), and the uptake of MMAs(III) and As(III) were much lower, amounting to 0.18% 
and 0.13%, respectively of initial substrate loading. As shown in Tables A.1-A.3, the highest 
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arsenic uptake was mostly detectable at relatively low concentrations (DMAs(III): 0.1 µM, 
MMAs(III): 5 µM, As(III): 0.5 µM) and this percentage decreases with increasing arsenic 
concentrations in the external medium. It might be that a defence mechanism exists in this 
case i.e. the extrusion of As(III) out of the cells and the prevention of an uptake at higher 
concentrations (Wang and Rossman, 1993; Wang et al. 1996). Detected arsenic concentrations 
in the whole-cell extract and in the cell-free (membrane removed) extract indicate no 
significant differences in the uptake of arsenic species for UROtsa cell lines. Therefore, it is 
concluded that no arsenic substrates bound to the cell membranes. The order of cellular uptake 
for the arsenic compounds in trivalent state was: DMAs(III) >> MMAs(III) > As(III). Similar 
differences between the uptake and/or retention of methylated trivalent arsenicals and As(III) 
have been found in primary rat hepatocytes (Styblo et al., 2000) and differentiated 3T3L1 
adipocytes (Drobna et al., 2005). A concentration-dependency was obsorved for all arsenic 
compounds. 
          The uptake capability of DMAs(III) by UROtsa cells were much higher compared to 
Hep G2 cell lines, but 3% lower compared to CHO-9 fibroblasts. 
 
4.3.2.2 Subcellular Distribution of Arsenicals in UROtsa Cell Lines  
          Cellular uptake of arsenicals in UROtsa cells have been studied (see 4.3.2.1 section). 
Further investigation has been focused on association and distribution of arsenic substrates 
after 1 and 24 h exposition with intracellular organelles (nucleus, mitochondria, plasma 
membrane and etc) in UROtsa cells. Results show that after 1 h exposition, the trivalent 
arsenicals were more effective than pentavalent one. Among the tested arsenicals, the highest 
percentage of total intracellular arsenic observed for MMAs(III) whereas 13% of this 
substrate was taken up by plasma membrane, 10.3% of DMAs(III), and 9.1% of As(III) of 
initial substrate loading, were taken up by nucleus and ribosomes, respectively. 
          Comparison of the pecentage of uptake by each organelle type after 1 and 24 h 
exposition is interesting. Results show, that the percentage of As(III) in the ribosomes 
increased very slightly after 24 h exposition to 10.7%. That means, only 1.6% was the 
difference of uptake capability by ribosomes. This can be concluded that uptake of arsenite by 
ribosomes may be occured very fast within 1 h, and as a result of that, the synthesis of 
proteins may be affected, because the ribosomes are the sites of protein synthesis, where RNA 
is translated into protein. Pyruvate dehydrogenase (PDH) is a multi subunit complex that 
requires the cofactor lipoic acid, a dithiol, for enzymatic activity. Arsenite inhibits PDH 
(Peters, 1955; Szinicz and Forth, 1988; Hu et al., 1998), perhaps by binding to the lipoic acid 
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moiety. Arsenite causes also enzymes inhibition through chemical reaction with thiol 
functional group of enzymes (Bredfeldt et al., 2004).  
          Subcellular distributaion pattern of MMAs(III) is different regards to changing of 
exposition time. Results show, that after 24 h expostion almost the same percentage of this 
substrate were taken up by plasma membrane and ribosomes, which compare to 1 h 
exposition ribosomes had 2.5 times more, and plasma membrane had 2.2% less uptake. In the 
ribosomes, MMAs(III) may play as an inhibitor for GSH-reductase (Styblo et al., 1997).  
          Up to 10.3% of total intracellular arsenic as DMAs(III) was taken up by nucleus at the 
expostion time of 1 h, whereas this amount decreased to 4.9% with inceasing the exposure 
time to 24 h. Inceasing the exposure time to 24 h, among the organelles, ribosomes has the 
major uptake capability with 7.2% followed by plasma membrane, and nucleus. Schwerdtle et 
al. (2003) observed oxidative DNA damage via trivalent methylated arsenicals in PM2 DNA 
and HeLa cells. DMAs(III) react rirectly with DNA, nicking naked DNA in vitro and 
damaging nuclear DNA in intact human leukocytes (Mass et al., 2001). Styblo et al. (2002) 
suggested that exposures to methylated trivalent arsenicals associated with a variety of 
adverse effects that have a profound impact on cell viability or proliferation. The known 
effects include a) inhibition of several key enzymes, b) demage of DNA structure, and c) 
activation of AP-1-dependent gene transcription. These authors reported that MMAs(III) 
and/or DMAs(III) derivatives are more potent than As(III) in producing these effects. 
          The percentage of arsenate, which has been taken up by plasma membrane and 
ribosomes were 13.9 and 10.0%, respectively at the exposure time of 24 h. Whereas, at the 
exposure time of 1 h , no arsenate was detected in plasma membrane, and low percentage of 
this metabolie was observed in ribosomes (2.1%). It might be, the chemical similarity of 
arsenate to phosphate explaines the relatively high percentage uptake of this metabolite by 
plasma membrane and ribosomes at the exposition time of 24 h. Arsenate like arsenite may 
causes inhibition of PDH enzyme and blocks cellular respiration (Szinicz and Forth, 1988). 
          In the case of MMAs(V), the percentage of this metabolite at the exposure time of 1 h 
in the organelles with the exception of plasma membrane is slightly higher compare to 24 h 
exposition. The highest percentage of detected DMAs(V) was in plasma membrane with 2.7% 
at the exposure time of 1 h. TMAsO was taken up to 8.3% by the ribosomes at the exposure 
time of 24 h and in the lower amount at the exposure time of 1 h. However, cytotoxic effects 
in the urothelial cells are not induced by pentavalent methylated arsenicals (von 
Recklinghausen et al., publ. in prep.).    
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4.3.3 HeLa S3 and Ra Hep Cell Lines 
          The pentavalent arsenic species were neither taken up by HeLa S3 nor by rat 
hepatocytes (Ra Hep) cell lines at different applied concentrations (0.5 µM to 5 mM). The 
trivalent methylated arsenic derivative MMAs(III) was the most membrane-permeable species 
among the tested arsenicals, whereas up to 1.22 and 0.75% uptake by HeLa S3 and Ra Hep 
cell lines from the external medium were shown, respectively, when the cells were cultured 
with 0.5 µM MMAs(III). The uptake of DMAs(III) and As(III) were lower amounting to 0.5% 
and 0.02% for HeLa S3, 0.4% and 0.35% for Ra Hep cell lines, respectively. As shown in 
Tables A.17-A.20, the highest arsenic uptake was mostly detectable at relatively low 
concentrations. It might be here like UROtsa cell line a defence mechanism exists (see 4.3.2.1 
section). Detected arsenic concentrations in the whole-cell extract and in the cell-free 
(membrane removed) extract indicate no significant differences in the uptake of arsenic 
species for these cell lines. Therefore, it is concluded that no arsenic substrates bound to the 
cell membranes. The order of cellular uptake for the arsenic compounds in trivalent state was: 
MMAs(III) > DMAs(III) > As(III). The uptake capability of DMAs(III) by these cell lines 
was much lower compared to other cell lines studied here (UROtsa, CHO-9, and Hep G2), but 
the uptake capability of MMAs(III) was comparable. 
 
4.3.4 Summary of Uptake Capabilities of Different Cell Lines 
          Different cell types have different capabilities for the uptake of arsenic compounds. The 
oxidation state and the degree of methylation of the arsenicals determine the uptake and 
subsequently the toxicity of the compounds. Table 5.1 (in summary section) shows the 
comparison of uptake capabilities of different cell types which have been studied here. As it 
has been shown in Table 5.1 trivalent methylated and inorganic arsenic species are more 
membrane-permeable than pentavalent arsenic metabolites and are taken up by these cells to a 
higher degree from the external medium. The present study revealed that trivalent arsenic 
metabolites [As(III), MMAs(III), and DMAs(III)] were best taken up by CHO cell lines and 
also in higher degree compared to other cell types which have been studied in this work. The 
order of cellular uptake of trivalent arsenicals by different cell types was: 
As(III): CHO-9 > Hep G2 > Ra Hep > UROtsa > Hela S3 
MMAs(III): CHO-9 > Hela S3 > Hep G2 > Ra Hep > UROtsa 
DMAs(III): CHO-9 > UROtsa > Hep G2 > Hela S3 > Ra Hep  
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It is interesting that the pentavalent arsenic species [As(V), MMAs(V), DMAs(V), and 
TMAsO] were not taken up by UROtsa, HeLa S3, and also by rat hepatocytes (Ra Hep) cell 
lines at different applied concentrations (0.5 µM to 5 mM). 
The order of cellular uptake (intracellular concentration of arsenic) of pentavalent arsenic 
compounds by CHO-9 and Hep G2 cell lines was as follows: 
As(V): CHO-9 > Hep G2 
MMAs(V) and DMAs(V): No significant difference was shown 
and finally the intracellular concentration of arsenic for TMAsO was higher in CHO-9 
compared to Hep G2 cell lines.   
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Summary 
 
          A speciation technique for anionic arsenic species has been applied using an ion pair 
reverse phase-high performance liquid chromatography coupled to inductively coupled 
plasma mass spectrometry (RP-HPLC-ICP-MS). Six arsenic species (arsenite, arsenate, 
dimethylarsinic acid, dimethylarsinous acid, momomethylarsonic acid, and 
monomethylarsonous acid) have been separated with isocratic elution within less than 6 
minutes. Furthermore, a cation exchange column was used for separation of AsB, AsC, tetra, 
and TMAsO. The chemical form and oxidation state of arsenic is very important with regards 
to toxicity, therefore analysis of total arsenic is insufficient for complete toxicological and risk 
assessment evaluation. Thus, arsenic speciation has been studied on some urine samples of the 
children from an arsenic-affected area in Iron Quadrangle, Brazil. DMAs(V) and MMAs(V) 
were the major urinary metabolites in these samples which have been detected. The mean 
value for total arsenic concentration of all urine samples analysed (n=15) is 26.33 ng As/mL 
with a range from 16.1 to 55.2 ng As/mL. TMAsO and AsC (arsenocholin) were not detected 
in any urine samples in this study. In the most of these samples, monomethylarsonous acid 
[MMAs(III)] was detected up to 2.0 ng As/mL. DMAs(III) was not detected at any time, most 
probably due to volatilisation and some oxidation to DMAs(V). The chromatographic 
recoveries calculated from [sum(species)×100]/total arsenic in urine samples were from 77.4 
to 94.9 percent. To validate the method, a certified reference material NIES CRM No.18 
human urine (National Institute for Environmental Studies, Tsukuba, Japan), the only CRM 
available for arsenic species in urine was analysed. Good agreement was obtained between 
certified and analyzed values for DMAs(V) and AsB in NIES CRM No.18. 
          More investigation has been made on identification of monomethylarsonous acid 
(MMAs(III)): (i) The retention time interval of MMAs(III) from the HPLC run with urine 
samples from Brazilian children exposed to arsenic-rich drinking water was cut off, and then 
by hydride generation at pH 5 volatilized. The GC separation led to clear isolation of 
MMAsH2 as proven by its mass frangmentogram compared with a library standard. This 
shows that the analyte is either MMAs(III) (MMAs(V) is separated by HPLC separation and 
not volatilized under the applied pH conditions) or a compound, which contains a MMAs(III) 
group that can be cleaved under the reaction conditions applied. Figure 3.9 show the 
chromatograms after hydride generation at pH 5. (ii) Mass of 48 and 50 monitored as sulphur 
oxide (48SO, 50SO) during arsenic speciation. The sulphur amount within the retention time 
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interval of MMAs(III) in urine sample was not significant on the background of the 
chromatogram. 
          Different cell types have different capabilities for the uptake of arsenic compounds. The 
oxidation state and the degree of methylation of the arsenicals determine the uptake and 
subsequently the toxicity of the compounds. Table 5.1 shows the comparison of uptake 
capabilities of different cell types which studied here. 
Table 5.1 Comparison of uptake capabilities of different cell types 
*HP: Highest Percent (detected As in whole-cell extract) & C: concentration (µM) 
**ND: not detected 
 
As it has been shown in Table 5.1 trivalent methylated and inorganic arsenic species are more 
membrane-permeable than pentavalent arsenic metabolites and are taken up by these cells to a 
higher degree from the external medium. The present study revealed that trivalent arsenic 
metabolites [As(III), MMAs(III), and DMAs(III)] were best taken up by CHO cell lines and 
also in higher degree compared to other cell types which have been studied in this work.    
 
 
 
    
           
        
   
Arsenic species 
 
 
 
Cell 
type 
 
As(V) 
 
As(III) MMAs(V) MMAs(III) DMAs(V) DMAs( III) TMAsO 
 
CHO-9 
HP* 
C 
 
1.99 
1 
3.83 
1 
0.03 
100 
1.78 
25 
0.02 
1000 
16.3 
0.5 
0.78 
1 
 
Hep G2 
 
HP 
C 
 
0.97 
0.5 
0.63 
0.5 
 
ND** 
1.16 
5 
0.63 
0.5 
4.17 
5 
 
ND 
 
UROtsa 
 
HP 
C 
 
ND 
0.13 
0.5 
 
ND 
0.18 
5 
0.02 
0.5 
13.27 
0.1 
 
ND 
 
Hela S3 
 
HP 
C 
 
ND 
0.02 
0.5 
0.05 
0.5 
1.22 
0.5 
 
ND 
0.46, 0.48 
0.5, (5, 10) 
 
ND 
 
Ra Hep 
 
HP 
C 
0.08 
0.5 
0.33 
0.5 
 
ND 
0.75 
0.5 
 
 
ND 
0.41, 0.46 
1, 10 
 
ND 
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Appendix 
 
Figure A.1 Calibration graphs of arsenic species 
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Table A.1 Uptake of sodium arsenite and sodium arsenate by UROtsa cells: whole-cell and 
cell-free extract. 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane removed) 
extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
As(III)     
control 0.10 ± 0.10 — 0.10 ± 0.10 — 
0.5 0.09 ± 0.05 0.13 ± 0.08 ND ND 
5 0.38 ± 0.04 0.05 ± 0.02 0.24 ± 0.07 0.03 ± 0.02 
50 1.93 ± 0.93 0.02 ± 0.02 1.67 ± 0.59 0.02 ± 0.01 
500 13.33 ± 0.08 0.02 ± 0.00 10.72 ± 1.20 0.01 ± 0.00 
5000 22.79 ± 2.41 ND 19.23 ± 0.66 ND 
As(V)     
control 0.13 ± 0.47 — 0.01 ± 0.31 — 
0.5 ND ND ND ND 
5 ND ND ND ND 
50 ND ND ND ND 
500 0.50 ± 0.26 ND 0.50 ± 0.21 ND 
5000 8.31 ± 1.28 ND 8.10 ± 1.62 ND 
 
 
Table A.2 Uptake of the trivalent organoarsenic species MMAs(III) and DMAs(III) by 
UROtsa cells: whole-cell and cell-free extract 
Detected As concentrations ± SD 
Whole-cell extract Cell-free (membrane removed) 
extract 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(III)     
control ND — ND — 
0.5 ND ND ND 0.05 ± 0.17  
1 0.09 ± 0.15 0.07 ± 0.11 0.38 ± 0.21 0.21 ± 0.03 
5 1.09 ± 0.40 0.18 ± 0.05 1.41 ± 0.69 0.23 ± 0.09 
50 19.61 ± 9.94 0.04 ± 0.02 21.96 ± 11.22 0.04 ± 0.02 
500 32.64 ± 6.23 0.01 ± 0.00 32.30 ± 9.85 0.01 ± 0.00 
DMAs(III)     
control ND — 0.48 ± 0.45 — 
0.1 1.99 ± 0.23 13.27 ± 1.51 1.96 ± 0.23 13.04 ± 1.56 
0.5 6.31 ± 2.18 8.41 ± 2.91 6.28 ± 1.29 8.38 ± 1.72 
1 10.82 ± 3.17 7.21 ± 2.12 10.98 ± 2.42 7.32 ± 1.62 
5 48.98 ± 11.59 6.53 ± 1.54 50.13 ± 11.47 6.68 ± 1.53 
10 76.56 ± 8.75 5.10 ± 0.58 79.20 ± 7.67 5.28 ± 0.51 
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Table A.3 Uptake of the pentavalent organoarsenic species MMAs(V), DMAs(V), and 
TMAsO by UROtsa cells: whole-cell and cell-free extract. 
Detected As concentrations ± SD 
Whole-cell extract Cell-free (membrane removed) 
Extract 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(V)     
control ND — ND — 
0.5 ND ND ND ND 
5 ND ND ND ND 
50 ND ND ND ND 
500 1.74 ± 1.55 ND 1.26 ± 1.32 ND 
5000 8.86 ± 4.49 ND 6.59 ± 3.27 ND 
DMAs(V)     
control ND — ND — 
0.5 0.01 ± 0.00 0.02 ± 0.00 ND ND 
5 ND ND ND ND 
50 0.07 ± 0.05 ND 0.08 ± 0.07 ND 
500 0.86 ± 0.36 ND 0.89 ± 0.30 ND 
5000 10.79 ± 1.65 ND 18.64 ± 13.40 ND 
TMAsO     
control ND — ND — 
0.5 ND ND 0.00 ± 0.00 ND 
5 ND ND 0.00 ± 0.00 ND 
50 ND ND 0.01 ± 0.01 ND 
500 0.16 ± 0.03 ND 0.24 ± 0.11 ND 
5000 0.98 ± 0.28 ND 1.04 ± 0.28 ND 
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Table A.4 Uptake of the 5 mM pentavalent organoarsenic species monomethylarsonic acid 
[MMAs(V)], dimethylarsinic acid [DMAs(V)], and trimethylarsenic oxide [TMAsO] by 
UROtsa cells, 1 h incubation. 
 
Detected As concentration  
Sample 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
MMAs(V) 
F 
N 
M 
P 
R 
C 
 
24.09 ± 3.55 
0.36 ± 0.32 
0.43 ± 0.10 
0.58 ± 0.43 
1.40 ± 0.91 
23.97 ± 1.52  
 
 
1.3 
1.6 
2.2 
5.2 
89.6 
DMAs(V) 
F 
N 
M 
P 
R 
C 
 
43.64 ± 2.11 
0.70 ± 0.14 
0.20 ± 0.15 
1.11 ± 0.35 
0.83 ± 0.11 
38.06 ± 6.15 
 
 
1.7 
0.5 
2.7 
2.0 
93.1 
TMAsO 
F 
N 
M 
P 
R 
C 
 
3.62 ± 1.62 
0.24 ± 0.32 
0.17 ± 0.06 
0.16 ± 0.00 
0.26 ± 0.07 
6.42 ± 3.75 
 
 
3.3 
2.3 
2.2 
3.6 
88.6 
 
Table A.5 Uptake of the 500 µM sodium arsenite and 5 mM sodium arsenate by UROtsa 
cells, 1 h incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detected As concentration  
Sample 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
As(III) 
F 
N 
M 
P 
R 
C 
 
107.26 ± 28.74 
1.04 ± 0.80 
0.55 ± 0.21 
0.99 ± 0.24 
7.77 ± 5.03 
75.25 ± 15.94  
 
 
1.2 
0.6 
1.2 
9.1 
87.9 
As(V) 
F 
N 
M 
P 
R 
C 
 
14.98 ± 0.04 
0.04 ± 0.07 
ND 
ND 
0.25 ± 0.12 
11.75 ± 0.92 
 
 
0.4 
— 
— 
2.1 
98.1 
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Table A.6 Uptake of the 500 µM monomethylarsonous acid [MMAs(III)] and 5 µM 
dimethylarsinous acid [DMAs(III)] by UROtsa cells, 1 h incubation. 
 
Detected As concentration  
 
Sample 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
MMAs(III) 
F 
N 
M 
P 
R 
C 
 
113.09 ± 42.95 
2.88 ± 1.69 
1.71 ± 0.64 
12.06 ± 5.24 
4.09 ± 3.26 
72.07 ± 19.80  
 
 
3.1 
1.8 
13.0 
4.4 
77.7 
DMAs(III) 
F 
N 
M 
P 
R 
C 
 
57.70 ± 11.18 
5.60 ± 5.19 
0.91 ± 0.27 
2.84 ± 1.79 
4.91 ± 1.08 
40.40 ± 7.30 
 
 
10.3 
1.7 
5.2 
9.0 
73.9 
 
Table A.7 Uptake of the 5 mM pentavalent organoarsenic species monomethylarsonic acid 
[MMAs(V)], dimethylarsinic acid [DMAs(V)], and trimethylarsenic oxide [TMAsO] by 
UROtsa cells, 24 h incubation. 
 
Detected As concentration  
Sample 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
MMAs(V) 
F 
N 
M 
P 
R 
C 
 
119.92 ± 0.78 
0.92 ± 0.06 
0.83 ± 0.16 
3.94 ± 0.05 
4.96 ± 0.02 
96.92 ± 3.01  
 
 
0.9 
0.8 
3.7 
4.6 
90.1 
DMAs(V) 
F 
N 
M 
P 
R 
C 
 
114.23 ± 8.56 
1.32 ± 0.29 
2.32 ± 0.40 
2.41 ± 0.94 
1.41 ± 0.81 
90.99 ± 2.15 
 
 
1.3 
2.4 
2.4 
1.4 
92.4 
TMAsO 
F 
N 
M 
P 
R 
C 
 
14.86 ± 0.85 
0.57 ± 0.12 
0.38 ± 0.01 
0.96 ± 0.07 
1.36 ± 0.13 
13.05 ± 0.19 
 
 
3.5 
2.3 
5.9 
8.3 
80.0 
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Table A.8 Uptake of the 50 µM sodium arsenite and 500 µM sodium arsenate by UROtsa 
cells, 24 h incubation. 
 
 
Detected As concentration 
 
 
Sample 
 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
As(III) 
F 
N 
M 
P 
R 
C 
 
7.08 ± 2.30 
0.31 ± 0.10 
0.26 ± 0.11 
0.43 ± 0.29 
0.83 ± 0.59 
5.96 ± 3.13  
 
 
4.0 
3.3 
5.6 
10.7 
76.5 
As(V) 
F 
N 
M 
P 
R 
C 
 
14.08 ± 1.36 
ND 
1.02 ± 0.03 
2.14 ± 1.54 
1.53 ± 0.14 
10.81 ± 2.43 
 
 
— 
6.6 
13.9 
10.0 
70.4 
 
 
Table A.9 Uptake of the 500 µM monomethylarsonous acid [MMAs(III)] and 5 µM 
dimethylarsinous acid [DMAs(III)] by UROtsa cells, 24 h incubation. 
 
 
Detected As concentration 
 
 
Sample 
 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
MMAs(III) 
F 
N 
M 
P 
R 
C 
 
35.88 ± 3.03 
7.01 ± 1.30 
1.16 ± 0.56 
2.04 ± 0.25 
1.43 ± 0.11 
20.77 ± 0.38  
 
 
21.6 
3.6 
6.3 
4.4 
64.1 
DMAs(III) 
F 
N 
M 
P 
R 
C 
 
11.16 ± 1.33 
0.53 ± 0.32 
0.22 ± 0.03 
0.73 ± 0.06 
0.78 ± 0.35 
8.69 ± 1.05 
 
 
4.9 
2.0 
6.6 
7.2 
79.4 
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Table A.10 Uptake of the 5 µM monomethylarsonous acid [MMAs(III)] and 5 µM 
dimethylarsinous acid [DMAs(III)] by UROtsa cells, 24 h incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detected As concentration 
 
 
Sample 
 
 
Detected As (ng per 10 6 
cells) ± SD 
% of total intracellular 
As in fraction 
MMAs(III) 
F 
N 
M 
P 
R 
C 
 
46.06 ± 2.64 
0.91 ± 0.16 
0.96 ± 0.23 
4.62 ± 0.30 
4.59 ± 0.35 
31.84 ± 3.17  
 
 
2.1 
2.2 
10.8 
10.7 
74.2 
DMAs(III) 
F 
N 
M 
P 
R 
C 
 
11.16 ± 1.33 
0.53 ± 0.32 
0.22 ± 0.03 
0.73 ± 0.06 
0.78 ± 0.35 
8.69 ± 1.05 
 
 
4.9 
2.0 
6.6 
7.2 
79.4 
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Table A.11 Uptake of the pentavalent organoarsenic species monomethylarsonic acid 
[MMAs(V)], dimethylarsinic acid [DMAs(V)], and trimethylarsenic oxide [TMAsO] by CHO 
cells: whole-cell and cell-free extract. 
Detected As concentrations ± SD 
 
Whole-cell extract 
 
Cell-free (membrane removed) 
extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(V)     
control 0.01 ± 0.02 — 0.02 ± 0.03 — 
1 <0.01 ND 0.02 ± 0.03 0.01 
10 <0.01 ND <0.01 ND 
100 2.92 ± 2.91 0.03 3.40 ± 2.89 0.03 
500 8.47 ± 2.00 0.01 8.15 ± 1.28 0.01 
1000 15.14 ± 0.02 0.01 15.24 ± 0.27 0.01 
     
DMAs(V)     
control 0.03 ± 0.04 — 0.05 ± 0.07 — 
1 <0.01 ND <0.01 ND 
10 <0.01 ND <0.01 ND 
100 0.23 ± 0.33 ND 0.50 ± 0.63 0.01 
500 5.61 ± 1.11 0.01 9.73 ± 1.78 0.02 
1000 18.68 ± 1.34 0.02 18.47 ± 2.00 0.02 
     
TMAsO     
control 0.22 ± 0.31 — 0.10 ± 0.14 — 
1 0.70 ± 0.27 0.78 5.01 ± 3.52 1.84 
10 0.07 ± 0.04 0.01 1.33 ± 0.78 0.13 
100 0.66 ± 0.93 0.01 0.84 ± 0.89 0.01 
500 5.29 ± 0.62 0.01 3.42 ± 1.31 0.01 
1000 8.14 ± 0.81 0.01 4.75 ± 5.21 ND 
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Table A.12 Uptake of sodium arsenite and sodium arsenate by CHO cells: whole-cell and 
cell-free extract. 
Detected As concentrations ± SD 
Whole-cell extract 
 
Cell-free (membrane removed) 
extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
As(III)     
control 0.13 ± 0.13 — 0.17 ± 0.29 — 
0.5 1.01 ± 0.43 1.41 0.71 ± 0.44 0.99 
1 5.15 ± 0.61 3.83 0.42 ± 0.42 0.31 
10 12.25 ± 1.17 0.97 9.80 ± 1.29 0.78 
100 55.65 ± 3.52 0.39 46.58 ± 0.42 0.33 
500 123.83 ± 8.09 0.18 105.51 ± 7.94 0.15 
1000 56.10 ± 1.64 0.41 57.03 ± 1.67 0.46 
As(V)     
control 0.13 ± 0.13 — 0.16 ± 0.28 — 
0.5 0.60 ± 0.10 1.02 0.47 ± 0.67 0.80 
1 2.03 ± 0.72 1.99 1.27 ± 0.14 1.24 
10 4.45 ± 0.47 0.40 3.94 ± 0.51 0.35 
100 24.09 ± 0.27 0.22 29.22 ± 0.95 0.26 
500 88.06 ± 3.78 0.16 76.03 ± 10.35 0.14 
1000 384.80 ± 91.31 0.32 359.89 ± 83.74 0.30 
 
Table A.13 Uptake of the trivalent organoarsenic species monomethylarsonous acid 
[MMAs(III)] and dimethylarsinous acid [DMAs(III)] by CHO cells: whole-cell and cell-free 
extract 
Detected As concentrations ± SD 
Whole-cell extract 
 
Cell-free (membrane removed) 
extract 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(III)     
control 0.05 ± 0.07 — 0.07 ± 0.09 — 
0.5 0.50 ± 0.70 1.01 0.19 ± 0.27 0.38 
1 0.78 ± 0.55 0.70 0.39 ± 0.07 0.35 
10 11.70 ± 4.82 1.02 11.20 ± 3.21 0.98 
25 55.40 ± 4.36 1.78 55.72 ± 1.93 1.79 
50 77.71 ± 14.14 0.91 80.14 ± 10.29 0.94 
DMAs(III)     
control 0.03 ± 0.04 — 0.10 ± 0.15 — 
0.1 <0.01 ND 0.07 ± 0.11 0.61 
0.5 8.35 ± 1.70 16.30 4.64 ± 0.69 9.06 
1 10.69 ± 7.50 9.44 6.80 ± 5.15 6.01 
5 45.84 ± 8.20 9.18 31.02 ± 1.69 6.21 
10 75.24 ± 7.52 6.90 57.15 ± 12.08 5.24 
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Table A.14 Uptake of sodium arsenite and sodium arsenate by Hep G2 cells: whole-cell and 
cell-free extract. 
Detected As concentrations ± SD 
Whole-cell extract 
 
Cell-free (membrane removed) 
extract 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
As(III)     
control ND — ND — 
0.5 0.68 ± 0.03 0.63 0.56 ± 0.02 0.52 
5 2.27 ± 0.00 0.27 2.13 ± 0.04 0.25 
50 10.71 ± 0.07 0.14 10.31 ± 0.04 0.14 
500 50.83 ± 0.24 0.05 47.50 ± 0.20 0.05 
5000 108.39 ± 5.00 ND 128.73 ± 1.24 ND 
As(V)     
control 0.02 ± 0.02 — 0.02 ± 0.02 — 
0.5 1.43 ± 0.03 0.97 1.54 ± 0.06 1.05 
5 0.46 ± 0.01 0.03 0.46 ± 0.03 0.03 
50 1.54 ± 0.03 0.01 1.51 ± 0.06 0.01 
500 4.71 ± 0.04 ND 4.43 ± 0.09 ND 
5000 21.86 ± 0.34 ND 20.65 ± 0.13 ND 
  
Table A.15 Uptake of the pentavalent organoarsenic species MMAs(V), DMAs(V), and 
TMAsO by Hep G2 cells: whole-cell and cell-free extract. 
Detected As concentrations ± SD 
Whole-cell extract 
 
Cell-free (membrane 
removed) extract 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(V)     
control 0.16 ± 0.19 — 0.02 ± 0.01 — 
0.5 ND ND 0.09 ± 0.04 0.07 
5 ND ND 0.11 ± 0.23 0.01 
50 ND ND 0.21 ± 0.02 ND 
500 0.56 ± 0.34 ND 2.10 ± 0.03 ND 
5000 14.11 ± 2.36 ND 25.15 ± 0.08 ND 
DMAs(V)     
control 0.03 ± 0.01 — 0.03 ± 0.00 — 
0.5 0.50 ± 0.91 0.63 0.07 ± 0.00 0.09 
5 0.17 ± 0.07 0.02 0.09 ± 0.11 0.01 
50 0.57 ± 0.12 0.01 0.37 ± 0.12 ND 
500 7.15 ± 0.00 0.01 6.67 ± 0.00 0.01 
5000 68.21 ± 0.19 0.01 66.19 ± 0.12 0.01 
TMAsO     
control 0.25 ± 0.06 — ND — 
0.5 ND ND ND ND 
5 ND ND ND ND 
50 ND ND ND ND 
500 ND ND ND ND 
5000 1.27 ± 0.10 ND 29.93 ± 0.26 ND 
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Table A.16 Uptake of the trivalent organoarsenic species monomethylarsonous acid 
[MMAs(III)] and dimethylarsinous acid [DMAs(III)] by Hep G2 cells: whole-cell and cell-
free extract 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane removed) 
extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(III)     
control 0.07 ± 0.02 — ND — 
0.5 0.95 ± 0.01 0.87 1.04 ± 0.01 0.96 
5 12.08 ± 0.18 1.16 10.55 ± 0.02 1.01 
50 84.74 ± 0.16 0.08 65.14 ± 0.13 0.06 
 
DMAs(III)     
control 0.09 ± 0.08 — 0.47 ± 0.00 — 
0.5 1.72 ± 1.80 0.67 0.94 ± 0.00 0.49 
1 3.18 ± 0.37 2.33 2.56 ± 0.00 2.06 
5 29.10 ± 0.07 4.17 33.46 ± 0.01 4.59 
50 82.65 ± 0.00 2.81 48.54 ± 0.00 2.09 
 
 
Table A.17 Uptake of sodium arsenite and sodium arsenate by HeLa S3 cells: whole-cell and 
cell-free extract. 
 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane 
removed) extract 
 
 
 
Conc. of As in 
exposure 
medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
As(III)     
control 2.20 ± 0.21 — 1.16 ± 0.28 — 
0.5 2.59 ± 0.02 0.02 ± 0.00 3.02 ± 0.23 0.02 ± 0.00 
5 9.62 ± 0.12 ND 3.26 ± 0.06 ND 
50 4.60 ± 0.14 ND 15.60 ± 0.61 ND 
500 68.68 ± 0.74 ND 65.82 ± 0.24 ND 
5000 160.87 ± 0.01 ND 160.11 ± 1.38 ND 
     
As(V)     
control 0.17 ± 0.13 — 0.17 ± 0.09 — 
0.5 0.01 ± 0.04 ND 0.42 ± 0.01 0.08 ± 0.00 
5 0.08 ± 0.03 ND 0.70 ± 0.04 0.01 ± 0.00 
50 0.73 ± 0.18 ND 1.04 ± 0.15 ND 
500 9.35 ± 0.09 ND 9.63 ± 0.09 ND 
5000 52.99 ± 0.36 ND 54.43 ± 0.35 ND 
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Table A.18 Uptake of organoarsenic compounds by HeLa S3 cells: whole-cell and cell-free 
extract. 
 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane 
removed) extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(III)     
control 0.08 ± 0.00 — 0.08 ± 0.00 — 
0.5 4.20 ± 0.01 1.22 ± 0.00 3.33 ± 0.05 0.96 ± 0.02 
5 21.22 ± 0.10 0.62 ± 0.00 18.04 ± 0.02 0.52 ± 0.00 
50 112.91 ± 0.82 0.33 ± 0.00 62.46 ± 0.31 0.18 ± 0.00 
500 160.19 ± 1.40 0.05 ± 0.00 61.58 ± 1.16 0.01 ± 0.00 
5000 190.08 ± 7.85 ND 85.92 ± 0.35 ND 
     
MMAs(V)     
control 0.52 ± 0.51 — ND — 
0.5 0.43 ± 0.03 0.05 ± 0.00 ND ND 
5 0.32 ± 0.00 ND 0.21 ± 0.01 ND 
50 0.06 ± 0.00 ND 0.27 ± 0.17 ND 
500 2.46 ± 0.00 ND 2.61 ± 0.00 ND 
5000 16.06 ± 0.23 ND 15.29 ± 0.02 ND 
     
DMAs(III)     
control 0.01 ± 0.09 — 0.12 ± 0.02 — 
0.5 3.43 ± 0.02 0.46 ± 0.00 3.11 ± 0.00 0.42 ± 0.00 
1 6.13 ± 0.00 0.41 ± 0.00 5.75 ± 0.00 0.39 ± 0.00 
5 35.28 ± 0.13 0.48 ± 0.00 33.77 ± 0.06 0.45 ± 0.00 
10 71.28 ± 0.26 0.48 ± 0.00 61.96 ± 0.12 0.42 ± 0.00 
   
DMAs(V)   
control 0.01 ± 0.02 — 0.02 ± 0.01 — 
0.5 ND ND 0.09 ± 0.01 0.01 ± 0.00 
5 ND ND 0.20 ± 0.01 ND 
50 0.50 ± 0.03 ND 0.92 ± 0.08 ND 
500 10.84 ± 0.05 ND 15.60 ± 0.21 ND 
5000 20.29 ± 0.10 ND 20.11 ± 0.10 ND 
     
TMAsO   
control ND — ND — 
0.5 ND ND ND ND 
5 ND ND ND ND 
50 ND ND ND ND 
500 ND ND ND ND 
5000 2.80 ± 0.00 ND 2.97 ± 0.00 ND 
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Table A.19 Uptake of organoarsenic compounds by rat hepatocytes (Ra Hep) cells: whole-
cell and cell-free extract. 
 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane 
removed) extract 
 
 
 
Conc. of As in 
exposure medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
MMAs(III)     
control 0.99 ± 0.00 — 0.99 ± 0.00 — 
0.5 39.79 ±11.77 0.75 ± 0.22 32.79 ± 9.48 0.62 ± 0.18 
5 352.52 ± 17.25 0.67 ± 0.04 325.92 ± 0.53 0.62 ± 0.00 
50 1055.61 ± 57.70 0.20 ± 0.01 813.54 ± 20.04 0.15 ± 0.00 
500 1165.90 ± 16.60 0.02 ± 0.00 788.76 ± 15.14 0.01 ± 0.00 
     
MMAs(V)     
control 0.30 ± 0.00 — 0.30 ± 0.12 — 
5 1.55 ± 0.42 ND 1.49 ± 12.65 ND 
50 0.19 ± 0.09 ND 0.09 ± 0.99 ND 
500 1.41 ± 0.00 ND 0.55 ± 0.82 ND 
5000 16.60 ± 0.25 ND 14.17 ± 0.14 ND 
     
DMAs(III)     
control ND — 0.04 ± 0.00 — 
0.5 4.12 ± 0.22 0.08  ± 0.00 3.13 ± 0.00 0.06 ± 0.00 
1 41.43 ± 1.22 0.41  ± 0.01 48.63 ± 0.00 0.48 ± 0.00 
5 17.15 ± 0.47 0.03  ± 0.00 24.09 ± 0.16 0.05 ± 0.00 
10 466.57 ± 4.27 0.46  ± 0.00 416.37 ± 2.54 0.41 ± 0.00 
   
DMAs(V)   
control ND — 0.05 ± 0.00 — 
0.5 ND ND 0.11 ± 0.18 ND 
5 0.15 ± 0.00 ND 0.09 ± 0.00 ND 
50 0.18 ± 0.04 ND 0.08 ± 0.00 ND 
500 4.38 ± 0.06 ND 4.30 ± 0.05 ND 
5000 33.13 ± 0.02 ND 32.30 ± 0.16 ND 
     
TMAsO   
control 2.84 ± 0.13 — 2.37 ± 0.26 — 
0.5 ND ND ND ND 
5 ND ND ND ND 
50 0.28 ± 0.00 ND 0.94 ± 0.00 ND 
500 13.43 ± 0.05 ND 14.64 ± 0.06 ND 
5000 169.73 ± 1.51 ND 169.82 ± 1.70 ND 
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Table A.20 Uptake of sodium arsenite and sodium arsenate by rat hepatocytes (Ra Hep) cells: 
whole-cell and cell-free extract. 
 
Detected As concentrations ± SD 
 
Whole-cell extract Cell-free (membrane 
removed) extract 
 
 
 
Conc. of As in 
exposure 
medium 
(µM) 
ng/106 cells % of arsenic 
substrate 
ng/106 cells % of arsenic 
substrate 
As(III)     
control 0.03 ± 0.01 — 1.47 ± 2.24 — 
0.5 2.91 ± 0.08 0.35 ± 0.00 ND ND 
5 10.99 ± 0.08 0.13 ± 0.00 3.90 ± 0.00 0.05 ± 0.00 
50 32.51 ± 0.56 0.04 ± 0.00 23.79 ± 0.00 0.03 ± 0.00 
500 37.98 ± 0.33 ND 27.48 ± 0.00 ND 
    
As(V)     
control 1.78 ± 0.64 — 0.67 ± 0.00 — 
0.5 6.29 ± 0.00 0.08 ± 0.00 7.70 ± 0.02 0.09 ± 0.00 
5 ND ND 2.50 ± 0.38 ND 
50 8.59 ± 0.03 ND 10.79 ± 1.07 ND 
500 78.79 ± 0.44 ND 75.88 ± 1.38 ND 
5000 345.08 ± 0.26 ND 345.84 ± 1.31 ND 
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